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Meningioma is the most frequent primary tumor of the central nervous system. The 
greatest percentage of meningiomas is benign tumors (WHO grade I). However, 
although surgical and radiotherapy techniques have significantly improved over the 
years, some meningiomas, independently from the grading, are refractory to 
multimodality therapies, and recur and/or undergo malignant transformation, 
representing an unsolved therapeutic challenge. Therefore, beside histopathologic 
benign appearance, biologically aggressive meningiomas need to be molecularly 
characterized, to identify novel therapeutic targets.  
In malignant tumors, recurrence is mainly ascribed to the presence of cancer stem 
cells (CSCs) which are expression of tumor cell heterogeneity, and sustain 
tumorigenesis, metastasization and drug resistance.  
CSCs are characterized by stem cell marker expression, self-renewal, and ability to 
differentiate into tumor-specific cell types. Recently, CSCs and their functional role 
have been also studied in benign tumors, including meningioma. A range of genes 
and proteins have been proposed to identify meningioma stem-like cells, among 
them CD105, a transmembrane glycoprotein, involved in angiogenesis and in the 
progression of a variety of tumors. Stemness, as well as cancer cell aggressive 
behavior, is a cell property strictly linked to tumor microenvironment: reciprocal 
interactions between growth factors, cytokines and chemokines released by both 
CSCs and other cell types forming the niche, modulate each other to sustain tumor 
growth. Chemokine signaling, and the CXCL11/CXCL12-CXCR4/CXCR7 system in 
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particular, drives cell proliferation and migration in several solid tumors. On these 
premises, this study is focused on the isolation and characterization of stem-like 
cells from post-surgical samples of human meningiomas, delving deeply into the 
role of this subpopulation in meningioma aggressive behavior. Moreover, we 
analyzed the contribution of CXCR4-7 receptors in the regulation of their biological 
properties. Twenty-eight primary cell cultures have been obtained from 35 
meningiomas, and maintained in stem cell-permissive culture conditions to enrich 
in CSCs. Putative meningioma stem cells rapidly grow, form meningospheres and 
express stem markers, such as Sox2, NANOG, CD133 and Oct-4. Conversely, CD105 
was not differentially expressed between stem-like cells and their “non-stem” 
counterpart, cells grown in serum-containing medium. Moreover, stem-like cells 
displayed high migratory capacity and in vitro angiogenic activity, supporting their 
malignant phenotype. Meningioma stem-like cells displayed a distinct chemokine-
receptor profile from “non-stem” cell population, and selectively respond to in vitro 
CXCL11 and CXCL12 stimulation enhancing proliferation, migration and vascular 
mimicry. Pharmacological inhibition of individual CXCR4 or CXCR7 significantly 
impaired CXCL12- and CXCL11-induced proliferation, chemotaxis and vessel-like 
structure formation, therefore suggesting that these activities are mediated by both 
receptors. We speculated that these receptors act as heterodimers, formed upon 
ligand activation and that the blockade of one of them results in a complete 
inhibition of biological effects.  
Overall our results, collected from a large number of meningioma cell cultures 
derived from different patients, allow the identification of a tumor subpopulation 
endowed with common stem cell-like features, and suggest that both CXCR4 and 
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CXCR7 signaling sustains meningioma stem cell phenotype. Prospectively, the 
isolation and culture of stem-like cells directly from the meningioma tissues will 
allow to test new therapeutic compounds to block meningioma growth and 
invasiveness, in particular for those tumors showing an unpredictable aggressive 
behavior. In this context, we propose that the CXCR4-7 chemokinergic system might 





Neoplasia is a term derived from the ancient Greek νέος (neo) "new" and πλάσμα 
(plasma) "formation, creation". Neoplastic cells are characterized by abnormal and 
transformed phenotype undergoing excessive proliferation. Neoplasms form 
uncontrolled and uncoordinated tissues, which continue to grow, depending on the 
host for their nutrition and blood supply.  
In the common medical language, a neoplasm is more frequently called tumor 
(swelling) and, the study of tumors is called oncology (from oncos, “tumor,” and 
logos, “study of”). Tumors are basically divided into benign and malignant subtypes, 
based on their potential clinical behavior. 
 Benign tumors: present non-aggressive gross characteristics, implying that 
they will remain localized and are susceptible to local surgical removal. 
Patients generally have a positive outcome.  
 Malignant tumors: are able to rapidly grow, invade and destroy adjacent 
structures, and to spread to distant sites through the metastatic process. 
They are referred to as a cancer, from the Latin word for "crab", for their 
ability to adhere to any part, similar to a crab's behavior. 
Cancer is a leading cause of death worldwide, and it has been recently reported that 
9.6 million deaths are estimated to have occurred in 2018 
(https://www.cancerresearchuk.org/health-professional/cancer-
statistics/worldwide-cancer#heading-One). Understanding the cellular and 
molecular abnormalities in cancer cells and the mechanisms involved in 
carcinogenesis, could represent a revolution in cancer treatment. In recent years, 
5 
 
basic and clinical research has moved in this direction, making important 
progresses, as detailed in the next paragraphs.  
1.1 BRAIN TUMORS 
Tumors arisen within the central nervous system (CNS) affect both young and adult 
people. Brain tumors encompass a larger proportion of childhood cancer, 
accounting for as many of 20% of all pediatric tumors.  
The annual incidence of CNS tumors ranges from 10 to 17 per 100,000 persons for 
intracranial tumors and 1 to 2 per 100,000 persons for intraspinal tumors; about 
half to three quarters of these are primary tumors, and the remaining are 
metastases from peripheral lesions. Statistical analysis shows that malignant CNS 
neoplasms are often aggressive, representing one of the main causes of tumor-
related death. 
It is important to stress that brain tumors cause many social and psychological 
burned, since beside health problems the quality life of patients is altered.  
Since even low-grade lesions may infiltrate large brain regions, serious neurological 
deficits represent the main symptoms, and if tumor cells spread to distant sites, the 
lesion cannot be radically resectable leading to a poor prognosis. Moreover, the 
anatomic site of these neoplasms can influence the clinical outcome independently 
from the histological classification due to local invasion and neurological effects (for 
example, a benign meningioma may cause cardiorespiratory arrest by compression 
of the medulla).  
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The 2016 CNS World Health Organization (WHO) classification includes molecular 
parameters, in addition to histology, to define tumor entities representing an 
important revision of the 2007 CNS WHO classification [1], as reported in the 
following Table 1.  









1.2.1 Pathological classification 
PATHOLOGY 
Meningioma is the most common primary intracranial tumor of arachnoid origin in 
the adult. In the past, several neoplasms currently classified as meningiomas were 
reported with different medical terms, depending on the area of origin of the 
tumor. In 1922, Harvey Cushing first used the term of “meningioma” to describe a 
set of brain and spinal cord tumors developed in proximity to meninges. 
The meninges, from ancient Greek μῆνιγξ (meninx), lit. 'membrane' are the 
membranes that envelop brain and spinal cord and their primary function is to 
protect the central nervous system. The three mammalian meninges are: dura 
mater, arachnoid mater and pia mater. Dura mater, the external layer, presents 
fibrous and resistant characteristics and, close to the skull adheres to the 
periosteum forming a single structure, the endocranium. Arachnoid, the middle 
meninges, is structurally similar to a spiderweb (from the Greek word “arachnoid”: 
spider), and is wet by the cerebro-spinal fluid (CSF). The pia mater is the inner 
meninges, directly in contact with the neuraxis. As previously mentioned, CSF is 
located between arachnoid and pia mater, acting as cushion for the brain to 
prevent mechanical injuries, immunological protection and regulation of cerebral 
blood flow. Brain choroid plexuses continuously produce about 500 mL of CSF per 
day which is absorbed in the arachnoid or in “Pacchioni” granulations.  
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Meningiomas manly originate from cells of the arachnoid cap (meningothelial cells). 
These cells are located at the apical part of the Pacchioni bodies and are exposed to 
the venous vascular flow, often within the dural sinus. In fact, arachnoid cells, 
characterized by high metabolic activity, are involved in reabsorption of CSF. 
Meningiomas usually develop as extra-axial tumors, occupying space within the 
cranial or spinal canal, but mostly are not able to invade the nervous tissue that is 
however shifted and compressed by the growing mass.  
CLASSIFICATION 
Meningiomas are among the most common intracranial tumors in adults (about 
37% of CNS tumors), showing high heterogeneity respect to histology, localization, 
clinical behavior and molecular features [2]. According to the 2016 WHO 
classification of tumors of the CNS [1], meningiomas are classified into three grades 
of malignancy showing an increased risk of recurrence. Despite the correlation 
between brain invasion and recurrence and mortality rates in WHO grade I 
meningiomas was described by Perry in 1997 [3], prior 2007 WHO classification 
considered invasion a staging rather than a grading feature, and opted to discuss 
brain invasion as a separate heading. In fact, classification and grading of 
meningiomas did not undergo substantial revisions, except for the introduction of 
brain invasion as a criterion for the diagnosis of atypical meningioma, WHO grade II. 
Moreover, the clinical value of such grading is limited, since it did not satisfactorily 
reflect tumor biology as well as the poor outcome and high recurrence rate (20%) 
observed in grade I meningiomas, or resistance to therapies and lethality observed 
in subgroups of patients, thus suggesting the need of molecular and genetic 
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characterization to identify prognostic markers to identify tumor subsets with 
divergent clinical behavior. WHO grade II and III tumors can arise de novo or 
develop from lower-grade meningiomas. 
Approximately more than 80% of meningiomas are benign and classified as grade I; 
4-15% are atypical (grade II) and 1-3% anaplastic (grade III) [3, 4], in which there are 
obvious malignant histological and cytological features such as increased cell 
proliferation and undifferentiated phenotype. Grade II include tumors displaying 4–
19 mitotic figures/10 HPF or brain invasion, or at least three of the following 
aspects: 
- increased cellularity; 
- small cells with a higher nucleus/cytoplasm ratio; 
- prominent nucleoli; 
- growth with an uninterrupted appearance or a sheet of paper; 
- spontaneous or geographical necrosis foci. 













Table 2 Meningioma subtypes according to WHO grade (2016 criteria) 
HISTOLOGICAL SUBTYPE WHO grade 
(2016 criteria) 
MENINGOTHELIAL I 
FIBROUS (fibroblastic) I 









CLEAR CELL II 
PAPILLARY III 
RHABDOID III 
ANAPLASTIC (malignant) III 
 
HISTOLOGICAL SUBTYPES OF MENINGIOMA 
The majority of meningiomas are slow-growing benign neoplasms identified as 
WHO grade I. As reported in the Table 2, meningiomas present a variety of 
histological subtypes, among which meningothelial, fibrous and transitional are the 
most frequent. In the meningothelial subtype, the lobules of tumor cells are 
surrounded by thin septa of collagen. From a cytological point of view cells seem 
arachnoid cap cells, but they show evident morphological alterations with oval or 
round nuclei with dispersed chromatin, smooth nuclear profiles and small indistinct 
nucleoli. Fibrous meningioma is characterized by elongated cells similar to normal 
fibroblasts, with the formation of extended bundles that intertwine with each 
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other. The collagen matrix can be present in different quantities. Finally, transitional 
meningioma has intermediate characteristics between above two subtypes, with a 
mixed lobular and fascicular conformation, often with spiral bodies.  
 
Figure 1 The most frequent histological subtypes of meningioma (grade I WHO) A) meningothelial; 
B) fibrous; C) transitional.  
Others grade I meningioma subtypes are: psammomatous, angiomatous, secretory, 
microcystic, lymphoplasmacytic and metaplasmatic. Clinically, there are not 
differences between these benign histological types as far as growth behavior and 
prognosis.  
Some histological subtypes are associated with a higher proliferative potential and 
recurrence rate and these correspond to the WHO II and III grades. Clear cell 
meningioma is a rare grade II subtype, presenting a benign histological appearance 
with an aggressive clinical outcome; WHO II chordoid meningioma resembles 
chordoma, a rare malignant bone tumor [5]. 
Anaplastic meningioma is characterized by histological and cytological aspects of 
evident malignancy, showing similar features to sarcoma, carcinoma or melanoma, 
and a higher mitotic index (20 or more mitosis per field) than atypical meningioma 
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[6]. Papillary and rhabdoid meningiomas are uncommon grade III subtypes, with an 
aggressive clinical course, high recurrence, metastatic diffusion, and mortality.  
 
MOLECULAR ALTERATIONS 
Recent studies show that the inclusion of new frequent molecular alterations in the 
diagnostic assessment might improve the identification of meningioma patients 
who need close surveillance and more-aggressive treatment [2]. Meningiomas 
display a high rate of copy-number alterations and karyotypic abnormalities. In 
particular, the most common cytogenetic alteration is loss of long arm of 
chromosome 22, which affects the neurofibromatosis 2 (NF2) gene, which encodes 
merlin, also known as schwannomin. Abnormalities in this gene result in the NF2 
familial syndrome, which is characterized by the development of benign tumors of 
nervous system [7]. 
Most neurofibromatosis-associated meningiomas have mutations of NF2 gene or 
loss of chromosome 22 [8], however non-NF2 tumors are also present, commonly 
displaying alterations of phosphatidylinositol-3-kinase and Sonic hedgehog 
pathways, TRAF7, KLF4 or POLR2A genes [9]. In WHO grade II and III tumors, beside 
some specific alterations (SMARCE1, BAP1, chromatin regulatory genes ARID1A and 
ARID1B), the most frequent mutation involves NF2 gene [9].   
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Table 3 Recurrent mutations observed in meningiomas. Modified from Bi W.L et al. 2018 
 
BAM 22, a member of -adaptin gene family, and MN1 genes, have been found 
frequently altered and, therefore, they are suspected of being involved in the 
initiation processes of meningioma development [10].  
Other cytogenetic abnormalities, are especially described in atypical meningioma, 
include losses of 1p, 6q, 10q, 14q, 17p and 18q and acquisition of 1q, 9q, 12q, 15q, 
17q and 20q [11, 12].  
Some interesting studies have shown association between the loss of the long arm 
of chromosome 14 and male sex, and a greater risk of recurrence among patients 
with benign meningioma [13]. 






As other intracranial tumors, meningioma aggressiveness and malignancy do not 
depend only on their histological grade, but also on the location. In fact, some 
benign lesions in “critical” brain regions could limit surgical access and serious 
symptoms might result from the “mass-effect” in vital cerebral nuclei. Patients mass 
that invades the brain tend to have a poor outcome.  
It is surgically difficult removing meningioma on the undersurface of the skull, in 
particular in regions adjacent to important brain structures and main vascular 
systems. Incomplete surgical resection and residual tumor cells are associated with 
a higher risk of tumor recurrence.  
The most frequent localizations of intracranial meningiomas are: 
 Falx and parasagittal (25%) 
 Convexity (20%) 
 Sphenoid wing (20%) 
 Olfactory groove (10%) 
 Suprasellar (10%) 
 Posterior fossa (10%) 
 Intraventricular (2%) 
 Intraorbital (<2%) 






At macroscopic level meningiomas grow as well-defined tumors. They present 
nodular, round or oval shape, red-grayish color and, homogeneous and often 
compact solidity. Meningioma usually compresses the brain without infiltrating it. In 
spite of this, extension into the overlying bone and infiltration into the parenchyma 
may be present, not necessarily constituting malignant properties. 
1.2.2 Epidemiology 
AGE AND SEX 
Meningiomas, with an estimated incidence of 7.86 cases per 100.000 people per 
year, primarily occur in elderly individuals, more frequently in the sixth and seventh 
decade, showing an increasing incidence over 65 years of age[14]. In adults, 
meningiomas preferentially affect women, with a female:-male ratio of 3.5:1 [15], 
which, in case of spinal lesions, rise to 10:1 [16].  
On the other hand, atypical and anaplastic meningiomas are more frequent in men 
at younger age (median 57-year old). The different incidence could be related to the 
hormonal profile or genetic difference although, nowadays, no definitive evidence 
confirms this hypothesis [17].  
In latest decades the incidence of meningioma is increasing, especially in elderly 
[18, 19]. This is certainly linked to a higher frequency of radiological investigations 
of the skull, to improved imaging techniques (computerized tomography and/or 
magnetic resonance imaging scan), and to increased population longevity [20]. In 
line with these assumptions, recent neuro-radiological registers report more new 
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cases of asymptomatic meningiomas casually detected in the elderly during analysis 
for different pathological conditions, but that, however, do not necessarily require 
surgery or hospitalization[21, 22].  
Meningiomas are rare in childhood, representing 0.4-4.1% of all pediatric tumors, 
and equally distributed in both female and male [15]. Moreover, the incidence of 
meningiomas is increasing among adolescents and young adults, representing   ̴16% 
of all intracranial tumors in people 15-39 years of age [14]. 
1.2.3 Etiological and risk factors 
GENETIC AND EPIGENETIC PREDISPOSITION  
A genetic predisposition is observed in meningioma is observed in rare hereditary 
cancer syndromes, such as the most neurofibromatosis type 1 and 2, Turner’s and 
Werner’s syndrome [23, 24].  
Neurofibromatosis type II syndrome, which is phenotypically characterized by the 
development of benign tumors of CNS, primarily schwannomas and meningiomas 
[7]. NF2-knockout mice develop spontaneous meningioma [25], endorsing NF2 as 
an initial oncogenic driver in both low- and high- grade meningioma tumorigenesis 
[26]. 
Besides, the losses of chromosome 1p and 14q are the second most frequent 
cytogenetic alterations observed in meningioma, and they affect 50% of grade II 
and almost grade III meningiomas [27, 28].  
In meningioma initiation processes other genes are involved: BAM 22, a member of 
the β-adaptin family, and MN1, which is frequently altered in meningioma [29], 
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TRAF7 (TNF receptor-associated factor 7), AKT1 proto-oncogene, KLF4 (Kruppel-like 
factor 4), PIK3CA oncogene, and SMO (Hedgehog pathway signaling member 
smoothened) [30].  
Patients with congenital and familial diseases, such as endocrine neoplasia type 1, 
Gorlin-, Cowden-, Gardner-, Turcot-, von Hippel-Lindau-, and Li-Fraumeni 
syndromes also have a higher incidence of meningioma.  
HORMONE RECEPTORS 
The highest incidence in women, the highest percentage of malignant meningiomas 
in men, the presence of progesterone (80%), estrogen (40%) and androgens 
receptors (39%) in these tumors, and the protective effects of pregnancy, suggest 
that sexual hormones play a role in meningioma development. In fact, 
epidemiological and biological data show a possible relationship between hormones 
and the risk of developing a meningioma. The preponderance of progesteron 
receptors (PRs) and the lack of estrogen receptors (ERs) in meningiomas are largely 
studied. The expression level of PRs in meningiomas determines a favorable clinical 
and biological outcome. Conversely, a reduction of PRs or the presence of ERs in 
meningiomas signals a higher presence of cytogenetic abnormalities, and an 
increasing aggressive behavior, progression, and recurrence [31].   
Exogenous hormones with contraceptive or hormone-replacement therapy appear 
to have not a significant protective effect. Nevertheless, studies show long-term 
hormone-replacement therapy implication in tumorigenesis [32][20]. 
Nevertheless, currently the role of hormone receptors and hormonal therapy use in 
meningioma development is still controversial and not definitely proven [17, 33], 
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partly due to the limited number of case reported and epidemiologic data 
heterogeneity. 
ENVIRONMENTAL FACTORS 
Electromagnetic Radiation  
In several epidemiological studies, exposure to ionizing radiation has been 
correlated with a higher incidence of meningioma. Treatment of tinea capitis of the 
scalp with low dose irradiation with 8 Gray (Gy), results in single or multiple 
meningiomas with an increased risk of 2.3% after a 35-year latency period [34]. 
Patients with gliomas, leukemias, lymphomas and/or brain metastases treated with 
radiotherapy, develop meningiomas after a slightly shorter median latency period 
(about 24 years). In general, meningioma induced by radiation exposure presents a 
more aggressive phenotype (about 50% are atypical). Among 80, 160 survivors to 
atomic explosions in Hiroshima and Nagasaki, 88 meningioma cases have been 
reported, corresponding to a risk of 6.48 times higher than the unexposed 
population [35]. 
Furthermore, exposure to low dose irradiation as dental x-rays appears responsible 
for an increased risk of meningioma [36-38]. In particular, dental X-rays performed 
in the past, when radiation exposure was greater than today, and performed 
frequently at a young age, appear to be associated with risk of intra-cranial 
meningioma [39]. 
Nowadays it is debated if chronic low exposures to mobile phone electromagnetic 
fields, classified as potential carcinogenic to humans by the International Agency for 
Research on Cancer, can be a potential risk factor for tumorigenesis. Studies report 
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conflicting data likely because the follow-up period relatively short, since emerging 
telecommunication techniques have become widely used only in the past 30 years, 
does not allow to provide consensus data [4, 20]. 
Chemical agent exposure  
Chemical agents and compound, such as hair dyes, have been hypothesized as 
potential risk factors for meningioma onset, although to date no statistically 
significant data have been reported.  
A harmful effect of lead has long been known as well as its connection to different 
brain tumors (in addition to those of stomach, lung and gallbladder), since this 
metal is able to cross the blood-brain barrier. Individuals exposed to lead constantly 
for professional reasons show a higher risk of developing meningioma than the 
unexposed population; in particular, this relationship involves subjects with ALAD2 
allele, because G177C ALAD polymorphism influences the toxic kinetic of lead [40].  
Head injury 
Accident- or crash-related head injuries may lead to several brain, skull, and blood 
vessels damages, involving a massive flow of cytokines, histamine and bradykinins 
in extravascular space due to local alteration of the blood-brain barrier. 
An analysis of approximately 3,000 people with head injury and 30,000 cases of 
control, the incidence of subsequent cranial tumors is not associated with the 
severity or location of the head damage [41]. Besides, the lack of etiological role of 
brain traumas in the onset of meningioma was also suggested by the observation 
than meningiomas are more common in women while cranial trauma are 2-3 times 




Most meningiomas have a good long-term outcome, however, the prognosis is 
variable among individuals on the basis of a complex background of tumor 
recurrence. The 5-years survival of benign meningiomas is about 70%, it declines in 
grade II and III (65%) and in older patients. Beside complete surgical resection the 5-
year recurrence rate of grade I meningiomas is about 20%, and 10-year recurrence 
is 10% in grade I, 30–40% in grade II and 50–90% in grade III. WHO grade III 
meningiomas, have a poor median overall survival of 1.5 years [42].  
High histological grade, papillary morphology, uncompleted surgical resection, age, 
male gender, low performance status, involvement of optical nerve, and a high 
mitotic index are prognostic factors associated with a higher rate of relapse [43, 44].  
The age of the patient influences the outcome. Generally, younger patients 
undergoing surgery recover better than older patients, in which more complications 
can arise. Tumor location and its surgical accessibility is a critical factor determining 
factor for patient survival, since radical resection cannot be always possible and, 
therefore, patients undergo partial resection allowing residual cells to re-grow and 
cause relapse [45]. 
A high mitotic index and early recurrence are often associated with meningiomas 
characterized by the absence of progestin receptors [46].In addition, chromosomal 
abnormalities and loss of heterozygosis are associated with lower survival and one 






Proliferative potential is measured with different proliferation markers, usually by 
immunohistochemistry with the monoclonal antibody MIB-1, which targets the 
antigen Ki-67. Ki-67 is a nuclear protein present only during active phases of the cell 
cycle (phases G1, S, G2 and M). Ki-67 index is calculated as a percentage of positive 
nuclei of tumor cells in relation to the total nuclei number examined in multiple 
microscopic fields [16]. Ki-67 expression is significantly related to a higher 
histopathological grade and an increased risk of recurrence in meningiomas [20, 
48]. However, although Ki-67 index may provide valuable additional prognostic 
information, it is not included in the classification criteria, in virtue of a high inter-
individual variability [49, 50]. 
Proliferative or tumorigenic potential of meningioma are also dependent on the 
levels of vascularization: a higher amount of vascular endothelial growth factor 
(VEGF) expression is significantly associated with meningioma vascularization and 
proliferation [51].  
1.2.4 Diagnosis 
Symptoms 
Despite their slow growth, intracranial meningiomas could remain completely 
asymptomatic for a long time. At the observation, many patients present a 
meningioma with a great bulk and poor or no neurological symptomatology.  
In some cases, due to the low correlation between tumor volume and clinical 
symptoms, the clinical history could be lasting for decades. Symptoms appear when 
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tumor bulk becomes so big to compress the intracranial structures. Independently 
from the tumor location, a slowly progressive intracranial hypertension syndrome 
invariantly occurs. Common symptoms are: headache, vertigo, nausea or vomiting 
and, papillary stasis. Less frequently, patients may develop transtentorial herniation 
and, cerebellar tonsils with loss of consciousness, uncontrolled eye movement, loss 
of respiratory capabilities, trouble talking, and epileptic seizures. A specific 
symptomatology, instead, is related to the specific meningioma location. The most 
frequent sites of tumor development are parasagittal and falx areas, followed by 
convexity and sphenoid wing. 
Compression symptoms are: focal seizures, edema and irritation of the cortex; 
these are followed by neurological deficits and signs of intracranial nerve 
involvement, especially in meningiomas grown in the cranial base.  
Imaging 
Nowadays there are no indications for a specific screening for meningioma 
detection. Patients with recent epileptic seizures or focal neurological signs, with 
suspected presence of an intracranial tumor mass, are examined by brain Magnetic 
Resonance Imaging (MRI). The majority of focal extra-axial masses are meningioma 
[52]. In many cases, standard radiography of skull, currently replaced by Computed 
Tomography (CT), is nevertheless able to highlight:  
- Meningeal vascular grooves dilatation and hypertrophy of the meningeal vessels 
due to increased vascularization;  
- Bone erosions or hyperostoses and, in some cases, an osteoma;  
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- Psammomatous tumor calcifications, although rarely, may define meningioma 
contour [53]. 
Angiography facilitates a precise visualization of tumor vascularization, including 
origin and location of tumor vessels. The typical pattern is the early appearance of 
contrast medium in the arterial phase and, its persistence in the venous phase. 
Angiography also helps in identifying occlusions of cerebral sinuses, mainly present 
in parasagittal and falx meningiomas.  
At CT and RM scans, meningiomas appear sessile, pedunculated or, more rarely, 
"carpet" at cranial base level and, due to high vascularization, they occur as 
isodense or hyperdense masses of dural surface with a mottled characteristic 
structure [53-55]. This aspect can be evaluated by digital bidimensional-angio RM 
for vessels visualization instead of trans catheter angiography [55, 56].  
By perfused MRI, peritumoral edema and vessels distribution have been studied in 
the interested brain area. Malignant histological features, large size, and basal 
localization are associated with a peritumoral edema, and correlated with a 
decreased blood flow in cerebral adjacent regions [57].  
By CT, psammomatous calcifications, which are not identified by MRI, are clearly 
evident.  
In radiological uncertain cases, for a "better" classification another diagnostic 
technique is MRI associated to alanine, high levels of choline and glutamine and low 
concentrations of creatinine, N-acetyl-aspartate and lipids spectroscopy [52, 58].  
In addition, before surgery, it is possible to use perfusion RMI, the arterial spin 
labeling technique, or the kinetic PET (positron emission tomography) providing 
information on the vascular supply of meningiomas [59].  
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1.2.5 Meningioma treatment  
Surgery 
Surgery represents the first choice treatment for symptomatic meningiomas and, 
generally, it is able to solve the majority of cases, relieving tumor mass symptoms 
and allowing histological diagnosis [52]. Conservative treatment or only observation 
by clinical and MRI follow-up, is indicated in small and asymptomatic meningiomas, 
especially in elderly patients [53]. All modern imaging techniques combined with 
neurosurgery and micro-neurosurgery make possible the successful removal of 
tumors previously considered non-operable, for difficulties in the surgical access, or 
for their strict connection with vital brain structures. 
The most reliable predictive factor of meningioma recurrence is the extent of 
surgical resection. For grade I meningiomas, Simpson grading scale plays an 
important role in guiding their treatment since 1957 [60]. Quality of the surgical 
resection is evaluated on the estimate extension of the resection through a 
classification still used and adapted according to the latest imaging techniques [52]. 
The extent of surgical resection, graded by the Simpson five-level system, is divided 
in: 
 grade I: total resection of tumor; 
 grade II: tumor is macroscopically totally resected and dural attachments 
coagulated; 
 grade III: total resection without coagulation of dural attachments or 
incomplete resection; 
 grade IV: partial resection with visible macroscopic tumor residue; 
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 grade V: biopsy.  
Current European Association of Neuro-Oncology (EANO, 2016) guidelines [61] for 
post-surgical treatment and follow up of meningioma patients are based on the 
Simpson grading and tumor grade (Table 4).  
Table 4 EANO guidelines for meningioma treatment with respect to WHO grade and extent of 
resections. Adapted from Goldbrunner et al., 2016. WHO, World Health Organization [9] 
 




Embolization results in tumor necrosis and it can be used preoperatively to separate 
tumor from highly vascularized tissues, as bone, dura mater and cerebral 
parenchyma. Furthermore, embolization reduces morbidity and mortality 
associated to intra-surgery bleeding.  
Arteries that spray a meningioma, mainly originate from the external carotid artery. 
An endovascular approach allows to reach and to remove tumor capillaries preserve 
in the arteries of healthy tissues. In this way, it is possible to avoid compromising 
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wound healing in the postoperative period [63, 64]. Embolization can also be taken 
into account as a palliative procedure [65]. 
Then, tumors shrink and become softer and easier to resect. Nevertheless, the 
overall risk of embolization is 5-6%. Accidental embolization of a particular vessel 
could determinate serious complications into the intracranial circulation or 
intratumoral hemorrhage or a cranial nerve injury. The common embolic agent used 
is polyvinyl alcohol (PVA). Large PVA particles have lower risk of penetrating 
adjacent tissues and causing stroke or cranial nerve palsy. Conversely, smaller 
particles get deeply into the tumor but may also migrate into normal tissue [66]. In 
addition to PVA particles, the Onyx liquid embolic agent can be used. Seven to 9 
days is the optimal timing for surgical procedure after embolization [67]; after that, 
there is substantial potential for the perfusion recovery of embolized vessels.  
Radiation therapy 
Irradiation represents first-line treatment, an adjuvant treatment, or a second-line 
treatment for recurrent meningiomas. Radiotherapy is the first-line treatment for 
skull-base meningiomas involving structures such as the cavernous sinus and the 
optic nerve, and as the only therapy when surgical approach is unfeasible.  
Meningioma cells are relatively radio-resistant but still, radiotherapy is the most 
effective adjuvant therapy available. Generally, fractionated radiation is used in a 5 
to 6 weeks treatment time, for partially resected benign meningiomas to sustain 
surgery and, usually total 50 to 60 Gy doses are needed to control the tumor growth 
for prolonged times. In atypical or malignant meningiomas and, in patients 
undergoing only partial tumor removal, fractionated radiotherapy is particularly 
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indicated [20, 52]. For these aggressive tumors, higher total doses are required 
fractionated radiotherapy (>54 Gy in 1.8 to 2.0 Gy fractions) [68]. In spite of the 
advantage offered by modern radiotherapy, neurotoxicity due to this treatment can 
potentially affect the quality of life of patients; in particular radiotherapy effects on 
pituitary gland, on cranial nerves and cognitive functions have not been completely 
defined yet [69].  
More sophisticated radiotherapy techniques allow a major disease control in about 
80 - 90% of cases. Generally, a total dose of 54 Gy (45-70 Gy) results effective and 
delayed further recurrence [70, 71]. Stereotactic radiation therapy (SRT) is a 
treatment that, through a high single dose, hit a small volume of the brain (about 
less than 3 cm) without affecting surrounding tissues. For these reasons, 
radiosurgery has recently become the first choice for well circumscribed, 
intracranial meningiomas and large inoperable tumors. CTT and MRI imaging 
techniques are used to better define the target volume to be hit by radiotherapy.  
In one or more therapy sessions, through a linear accelerator or, in a single fraction 
therapy using a gamma-knife, SRT permits to attack tumors close to critical area 
such as cranial nerves, making resectable tumors that can only partially be removed 
by surgery [72]. Stereotactic radiosurgery (SRS) with the gamma knife technique, is 
currently widely used to treat intracranial meningiomas of size<3–4cm. SRS 
determines common side effects such as cranial nerve defects and peritumoral 
edema and more rarely necrosis, peritumoral cyst formation, carotid artery 




MEDICAL TREATMENT FOR RECURRENT MENINGIOMAS 
Chemotherapy 
Systemic therapies are used after surgery and radiotherapy failure, however 
effective drugs for meningiomas are presently lacking [74].  
Therefore, chemotherapy is rarely used in the treatment of meningiomas, as 
adjuvant treatment after surgery and radiotherapy [28]. Short- and, mainly, long-
term effects such as lymphomas and leukemias, pulmonary fibrosis, renal 
insufficiency and neurotoxicity justify the chemotherapeutic approach only in a 
minority of cases. Classical cytotoxic drugs (temozolomide, irinotecan, doxorubicin, 
ifosfamide) did not improve patients' outcome [74]. Furthermore, since benign 
meningiomas have a slow growth rate, it is difficult to evaluate the effect of 
chemotherapy. 
Hydroxyurea (HU), a ribonucleotide reductase inhibitor, used in patients who 
underwent complete tumor resection at 20 mg/kg/day, was able to prevent 
malignant meningioma recurrence for 24 months [75, 76]. Subsequently, numerous 
clinical reports on patients with recurrent or progressive meningioma revealed 
efficacy of HU antitumor treatment [77].  
In a study, after treatment with HU, 18 out of 20 patients exhibited a stabilization of 
the pathology and a partial response in 2 cases, for an observational period of 80 
weeks. Hematological side effects have often arisen, mainly characterized by 
neutropenia [78].  
Moreover, in 12 benign meningioma cases, the disease was stabilized and two of 
patients showed clinical improvement. One patient manifested a minor partial 
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response that was noted after 3 years of treatment on neuroimaging and clinical 
evaluations. Chemotherapy was generally well tolerated, although in some patients 
a minor haematological toxicity was reported, and only one patient interrupted 
therapy due to moderate myelo-suppression [79]. Another clinical trial reports 
benefit in the majority of patients treated with HU: 11 of 15 patients obtained a 
stabilization of the disease for a median duration of 11 months [80].  The disease 
stabilizing effects of HU have not been confirmed by other studies.  Hydroxyurea 
only has showed a stabilizing activity in some series [70–72], but this has not been 
consistently confirmed [81, 82].  
Several small phases II studies using a combination treatment of HU with other 
chemotherapeutic agents as imanitib did not reported effects on patients’ survival 
[83].  
Verapamil, a calcium channel antagonist, known to augment the effects of 
chemotherapy drugs through the inhibition of the extruding pump P-glycoprotein, 
combined with HU, reduce vascularization, size and cell proliferation with an 
increase of apoptosis rate [84].  
The post-radiation co-treatment with cyclophosphamide, adriamycin and vincristine 
(CAV), caused a very modest improvement in the median survival of 5.3 years 
respect to a median survival of 2.7 years in a group of patients who received 
subcutaneous octreotide three times per day; nevertheless co-treatment CAV was 
associated with high toxicity [28]. In particular, different chemotherapy-related 
complications occurred as transient alopecia, anemia, thrombocytopenia, and 
neutropenic fever; however, no bladder or cardiac toxicity appeared and no 
patients died as results of chemotherapy-related toxicity [85].  
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Temozolomide (TMZ), a chemotherapeutic agent used to treat glioblastoma 
multiforme (GBM) and astrocytomas, is not effective in recurrent meningiomas 
[86].  
Irinotecan, an antitumor drug especially used to treat colon and small cell lung 
cancers, showed anti-proliferative activity both in vitro in meningioma cell cultures 
and in vivo in animal studies, but no clinical efficacy was observed in a phase II 
clinical trial [87].  
Targeted Therapy 
Nowadays, little is known about the signal transduction pathways, the growth 
factors and their receptors involved in meningioma proliferation [88, 89].  
Many studies, to evaluate possible novel molecular target driving cell growth, 
proliferation and angiogenesis, are ongoing. Meningiomas present aberrant 
expression of signaling molecules and deregulated cell signaling pathways as a 
driver of neoplastic transformation [28, 90, 91]. For example, Hedgehog (Hh) 
signaling pathway, crucial for embryogenesis and cellular growth, is significantly 
activated in some meningiomas [92]. Serine/threonine protein kinase AKT pathway 
regulates several cellular processes as crucial tumor proliferation and survival, 
tissue invasion, and resistance to chemotherapy. AKT, highly expressed in skull base 
meningioma, has been reported [93].  
Hormonal Therapy 
Women have a higher incidence of developing meningioma, especially after puberty 
and during their most fertile years. Moreover, the higher incidence in meningioma 
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reported among breast cancer patients support the potential role of hormones in 
both diseases and drugs used for breast cancer treatment have been used for 
hormone manipulation in meningioma.  
Tamoxifen, an oral anti-tumor drug largely used in breast cancer patients, belongs 
to the selective estrogen receptor modulators (SERMs) family, and inhibits the 
estrogen effects by deacetylating histones and blocking DNA binding to estrogen-
receptor. However, in meningioma patients tamoxifen did not significant response 
in term of tumor growth inhibition [94, 95]. The PR inhibitor mifepristone (RU486), 
a potent contraceptive designed in the 80's and predominantly used to induce early 
pregnancy interruption, acts at lower concentration than progestogens by inhibiting 
the transcriptional activity of the progesterone receptor [96].   
The use of progesterone antagonists as palliative treatment for meningiomas is 
controversial. In few small trials, positive results were obtained [97, 98]. A 
prospective study by SWOG (Southwest Oncology Group) on 193 patients whose 
state of PR was unknown in 138 out of 193 patients, 80 patients were treated with 
mifepristone at a dose of 200 mg and 80 with placebo, for a median period of 10 
months. Grade IV toxic and side effects were detected in 6 mifepristone-treated 
arm patients and in a placebo-treated arm patient. Grade III toxicity has been 
described in 30 mifepristone-treated patients and in 24 placebo-treated patients. 
The toxic effects were mainly constituted by hypostenia (72% versus 54%), 
headache (44% versus 41%), and flushing (38% versus 26%). A large number of 
female patients also presented endometrial hyperplasia [99].   
Somatostatin receptors are also expressed in the majority of meningiomas [100]. In 
vitro, somatostatin inhibits meningioma proliferation. Preliminary study of 16 
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patients has shown a partial response to somatostatin treatment of one third of 
patients. In a phase II trial, subcutaneous treatment with octreotide, a somatostatin 
receptor agonist, resulted in 17 weeks PFS and a median survival time of 2.7 years 
in 11 patients with recurrent meningioma compared to previous trials that reported 
a median survival time of well under 1 year [101]  [102].  Octreotide is also under 
study in combination with everolimus, a drug targeting the mTOR-pathway whose 
activity in meningioma cells has been proven in vitro [103], in recurrent tumors. 
Anti-Angiogenic treatment 
Blood vessels play an essential role in tumor nutrition. Meningiomas are 
characterized by high vascularization and, therefore, blood vessel formation 
represents a potential therapeutic target. For example, anti-angiogenic drug 
fumigillin analogue (TNP-470) inhibited the growth of benign and malignant 
meningioma in xenografts animal models [104].  
Vascular endothelial growth factor (VEGF) is the most important molecule involved 
in tumor vascularization and anti-VEGF drugs are used in different cancer types 
[105, 106]. VEGF and VEGF-receptor expression is directly proportional to 
meningioma grading. In fact, atypical and malignant meningiomas express 2- and 
10- fold higher levels of VEGF, respectively, than benign meningiomas [107]. The 
anti-VEGF antibody bevacizumab has been largely tested in clinical trials 
representing a well-tolerated treatment. Partial regressions have been reported in 
anaplastic meningioma, in which patient received bevacizumab intravenously every 
two weeks for 15 months after non-curative surgeries [108] and, in a NF2-deficient 
meningiomas [109]. A group of 15 bevacizumab-treated patients with atypical or 
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malignant meningiomas, reported a median PFS of 26 weeks, and PFS6 rate was 
43.8% compared to a group of 10 imanitib-treated patients, in which the median 
PSF of 8 weeks, and PSF-6 rate of 0%, and to a group of 17 patients treated with the 
anti-somatostatin receptor agonist Pasireotide, in which the median PFS was of 16 
weeks, and a PFS-6 rate was 20% [110] and a decreased tumor blood volume. 
Another retrospective study conducted on 15 patients with recurrent atypical and 
malignant meningioma and treated with bevacizumab, reports a PFS6 of 86% 
respect to a PFS6 of 10% observed in patients treated with the ribonucleotide 
reductase inhibitor (HU) [111]. Although well tolerated, different side effects such 
as CNS hemorrhage and/or intestinal perforation occurred due to bevacizumab 
treatment [111]. 
A phase II clinical trial on 36 patients with grade II and III meningioma was also 
performed using the VEGFR and PDGFR inhibitor sunitinib. Unluckily, 60% of 
patients suffered from grade III toxicities, 32% of them needed dose reduction, and 
22% of patients had to interrupt the treatment [112].  Twenty-five patients with 
benign, atypical and malignant meningioma were also treated with four cycles of 
vatalanib (PTK787), another VEGFR and PDGFR inhibitor. Vatalanib proved to be 
safer and less toxic than sunitinib prolonging PFS; in patients with recurrent Grade II 
and III meningioma treated with sunitinib the median PFS was of 4.6 months, 
instead patients treated with vatalanib the median PFS was of 7.6 months, [113]. 
These promising results should be confirmed in larger prospective phase III 





Several evidence supports that interferon-alpha (IFNα) promotes the inhibition of 
meningioma cell proliferation in vitro [114-116]. Only small studies, however, 
demonstrated the IFNα effect on the progression of recurrent and unresectable 
meningiomas. Interferon-alpha helps stabilizing or diminishing recurrent 
meningiomas. Five of six patients treated with IFNα for five days a weeks showed 
stable disease up to 14 months and, only one had minor reduction of the tumor 
[117]. Another report reveals a stable disease up to 8 years in 9 out of 12 patients 
[115]. Recently, in a larger study, involving 35 patients with grade I recurrent 
meningioma, 10 patients had some toxic effects and, consequently, a reduction of 
the drug dose; 25 patients had a stable disease with median time to tumor 
progression of 7 months. On the other hand, 9 patients progressed with a median 
survival time about of 8 months [118]. The outcome of INF-α treated patients is 
quite various and unpromising [107, 119, 120].   
Meningioma animal models, such as transgenic mice in which NF2 and CDKN2ab are 
inactivated, might be helpful to further evaluate the therapeutic efficacy of 
interferons [121]. 
Oncolytic Virus 
An emerging medical treatment for different tumors is the use of oncolytic virus 
(OV) to determine an anti-tumor cellular immune response. This type of virus is able 
to kill selectively tumor cells. Actually, different OVs, including adeno and herpes 
simplex (G47D) viruses, have been investigated in preclinical meningioma models. 
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G47D is also in clinical trials for recurrent glioblastoma and in schwannoma, and 
preliminary results suggested its safety and encouraging efficacy [122, 123].  
Immunotherapy  
The most recent medical strategy in oncology is represented by immunotherapy, 
based on the inhibition of immune checkpoint modulatory molecules, whose 
expression has been detected also in PD-L1-cell infiltrating aggressive meningiomas 
[124].  Clinical trials are ongoing with the anti-PD-1 agents nivolumab agents 
nivolumab, pembrolizumab (NCT03173950) and avelumab (in combination with 
radiotherapy) in relapsed high-grade meningiomas. 
LONG-TERM TOXICITY OF THERAPEUTIC APPROACHES  
Cognitive and neurological deficits may have a significant impact on patients with 
brain tumors, independently from the histological subtype and grade of neoplasia. 
In particular areas, surgery causes cognitive deficits: the major problems are loss of 
memory, apathy, difficult in concentration and personality changes. Radiotherapy 
effects on cognitive functions are still unclear likely due to the difficulty to 
determine if deficits were induced by the tumor or the treatment [125, 126]. A 
recent study in patients with low-grade progression-free glioma did not confirm 
correlation between radiotherapy and cognitive deficit [127]. Only relationships 
between cognitive deficits and antiepileptic drugs have been identified. Epileptic 
seizures have a significant impact on the quality of life despite an effective control 
of the disease. New antiepileptic drugs with fewer side effects can be useful 
especially in patients under multi-chemotherapeutic treatment.  
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Radiotherapy can damage cranial nerves or induce endocrine dysfunction, also 
when the treated neoplasia is distant from the hypothalamic pituitary region [128]. 
Therapies also increase the risk of mortality. Chemotherapy induces late side 
effects, such as lymphomas, leukemia or solid tumors, pulmonary fibrosis, kidney 
failure, infertility and neurotoxicity. Also radiotherapy, at doses over 54 Gy, has a 
risk of mortality about of 2.5% at 2 years. In addition, at high and widespread doses, 
more than 5% of patients may present radio-necrosis, causing blindness if adjacent 
to the optic chiasm.  
FUTURE PERSPECTIVE 
The high frequency of recurrence and, the absence of an effective pharmacological 
therapy, for both benign (grade I) and malignant (grade II and III) tumors, are 
stimulating challenge for clinical management of these tumors. Moreover, both 
ongoing basic and preclinical research, foster new knowledge on these tumors. An 
interaction between clinical, epidemiological, pharmacological, genetic and 
biological research has recently allowed a therapeutic improvement constantly 
evolving; nevertheless, the persistent problem requires further insight.  
1.3 STEM CELLS 
Differentiated tissues are composed by heterogeneous cell subpopulations, and are 
constantly renewed through the differentiation of stem cells [129]. A balance 
between the replication, self-renewal and differentiation of stem cells and the 




Two important features characterize stem cells:  
 self-renewal: to maintain a relatively constant number of functional 
population of precursors for long periods of time by asymmetric replication: 
the ability to produce two types of daughter cells. One cell begins the 
differentiation pathway, giving rise to the progenitors and mature cells 
composing different organs, while the other cell retains its stemness 
preserving its self-renewal ability.  
 differentiation into multiple lineages on more mature cells. 
Moreover, stem cells display higher resistance to cytotoxic agents, included drugs, 
than differentiated cells, due to their high ability to repair DNA and the high activity 
of membrane transporters. 
Normal stem cells can be identified according to the origin and the differentiation 
potential, but they can be essentially and divided into two types:  
 Embryonic stem cells (ESCs), derived from the inner cell mass of the 
blastocyst; ESCs are pluripotent, representing the descendants of totipotent 
cells, they give rise to all the cells in the adult organ. According to different 
physiological conditions, ESCs form specialized cells of all three germ layers: 
endoderm (stomach and gastrointestinal lining, and lungs), mesoderm 
(muscles, bones, blood, and urogenital system), and ectoderm (epidermal 
tissues and neuronal lineages, as neurons, astrocytes and oligodendrocytes). 
Due to their extensive cell renewal ability, under different environmental 
stimuli ESCs can generate several lineage-committed progenies, generally 
maintained during the lifespan of organism. The potentially unlimited 
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capacity of self-renewal and plasticity have been considered the bases for 
the development of embryonic stem cell therapies. In particular, ESCs have 
been proposed for regenerative medicine and tissue replacement after 
injury or disease.  
 Adult stem cells, comprising somatic stem cells (SSCs) and germ stem cells 
(responsible for spermatogenesis and oogenesis). 
o SSCs are responsible for tissue homeostasis, and regeneration after 
injury of the organ in which they reside, are multipotent (able to 
generating multiple differentiated cell types of a particular 
tissue/system) or unipotent [130]. SSCs are present in tissues with 
both high (skin, bone marrow, etc.) and low cell turnover (such as 
heart and blood vessels).  
Clonogenic assay enable stem cells isolation through the ability of single cells to 
differentiate and self-renew [131, 132]. Nowadays, researchers try to define a 
distinctive set of cell surface markers. 
Of great interest is also the characterization of the stem cell niches, specialized 
microenvironments involved in the preserving cell stemness and providing the 
stimuli for their activation to generate differentiated cells. In adults, stem cell 
niches are different from each other as far as cellular composition, structure, and 
localization. The balance between self-renewal and differentiation is allowed by the 
conservation of biological properties through a specific interaction between stem 
cells and their niches. 
Alterations in the niche cellular microenvironment are critical for tissue 
homeostasis and have been involved in the trigger of the oncogenic process.  
40 
 
1.3.1 Cancer stem cells 
Stem cells are a key element not only for developmental biology and regenerative 
medicine, but also in cancer biology.  
Tumor contain cell subpopulation at variable state of differentiation giving high 
intra-tumor heterogeneity: a major subpopulation of differentiated tumor cells 
forming the tumor bulk; and a smaller subpopulation of undifferentiated CSCs self-
renewing and able to differentiate. These two cell subsets show different gene 
expression, tumor propagation potential, and response to therapy, likely due to 
genetic and epigenetic modulations, metabolic features and microenvironmental 
factors  [133]. 
The traditional theory of carcinogenesis based on the stochastic hypothesis, in 
which the same tumorigenic potential is maintained by all cells within the tumor 
mass, has been replaced by the hierarchical model after the CSC detection, isolation 
and characterization [134, 135]. CSCs may derive from normal SSCs after genetic 
alterations and/or from microenvironmental stimuli [136]. CSCs sustain the 
malignant properties of tumors, including chemo- and radio-resistance, aberrant 
regulation of cell survival, proliferation, differentiation, migration, and tumorigenic 
activity. In fact, several different studies demonstrate that only CSCs are able to 
initiate tumor in immuno-deficient mice. 
In malignant tumors, recurrence is due to the presence of CSCs that play an 




The role of CSCs in cancer has been described in hematologic malignancies, head 
and neck carcinomas, brain tumors, colon cancer, melanoma, liver, prostate, and 
ovarian [139, 140]. The definition of CSC is challenging since purification and 
characterization methods have limitations therefore CSCs are functionally defined 
by their ability to self-renew and differentiate, and form a tumor which 
recapitulates the hierarchical cell structure and heterogeneity [141].  
Tumor microenvironment, containing different cell types including CSCs (niche) is 
gaining a relevant role for CSC survival and proliferation; each tumor niche although 
composed by specific cell subset shares some cell phenotype, epigenetic regulation 
and signaling pathways, modulating CSC-niche reciprocal crosstalk [136].  
 CSC model has led to novel therapeutic goals in to safely eradicate CSCs without 
affect normal SSCs. 
1.3.2 CSC markers 
Although in the last years CSCs have been successfully characterized in several 
human and animal tumors, a specific population of CSCs within a given tumor, 
showing homogeneous cellular and molecular properties has not been identified 
yet. The lack of specific CSC markers contributes to the still elusive characterization 
of CSCs; therefore, currently only a panel of putative markers that enrich for 
stemness different tumors is available.  The expression of stemness markers, such 
as NANOG, OCT4, and SOX2, have been reported in different tumors such as oral 




An in-depth study of the molecular mechanisms involved in the proliferation of CSCs 
and the detection of selective markers allowing the identification of this 
subpopulation, are important goals for the investigation of new possible 
therapeutic targets. 
Recently, CSCs and their functional role have been also studied in benign tumor, 
suggesting that also benign tumor initiating cells are endowed of niche-dependent 
plastic functions, regulated by epigenetic events and signaling pathways. A cell 
subpopulation within both hormone-producing and non-functioning pituitary 
adenomas, characterized by self-renewal ability, and expressing neural stem cell 
marker such as nestin, CD133, DCX, TUJ-1, and Musashi-1, was proposed to be 
responsible for benign tumor initiation and maintenance [145].  
In particular, a subpopulation of CD133+-cells, selected by growth in stem-cell 
permissive medium, has shown persistence of self-renewal, high proliferative 
potential and in vivo tumorigenic activity [146]. 
The expression of CD44 and CD54 in lipoma cell lines explained the ability of local 
tumor progression and the rich neo-angiogenesis development [147]. Still in lipoma 
tissue, CD34 positivity is combined with higher replicative ability and maintenance 
of cell immaturity, acting on stroma formation and synthesizing and remodeling the 
extracellular matrix [147]. 
 CD34 cells also promote angiogenesis through the secretion of VEGF, PDGF and IL-8 
[148, 149]. In hemangiomas, the most common benign vascular tumor of childhood, 
characterized by rapid growth and slowly spontaneous involution,  several studies 
suggested the presence of tumor proliferating cells expressing stem markers such as 
CD29, CD44 and CD105, and mesenchymal stem cells [150-152].  
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1.3.3 CD105 as a putative meningioma stem cell 
marker 
Several putative stem markers have been described in the isolation and 
characterization of tumor stem-like cells from human meningioma such as CD133 
[153-156], stage-specific embryonic antigen-4 (SSEA4) [155], Sox2 [157] and CD44 
and nestin [158]. Self-renewal ability, spherogenesis, and in vivo tumorigenesis was 
also reported [159].  
These studies open the possibility that also in meningioma a cell subpopulation 
endowed with stem-like properties could be at the basis of the tumor generation, 
progression and recurrence in those forms with atypical clinical behavior. Although 
definite stem markers for meningioma are still lacking, CD105 expression has been 
proposed as potential target to identify the meningioma subpopulation responsible 
of the benign tumor recurrence.  
CD105, also named endoglin, is an 180kDa homodimeric transmembrane glycol-
protein, belonging to the TGF- receptor complex. CD105 is significantly expressed 
in condition in which angiogenic activity is highly activated, such as in renewing of 
inflamed tissues, or in tumors. Many evidences show that CD105 expression is up-
regulated by hypoxia [160] and, in solid tumors, anti-CD105 immunoreactivity 
tightly matches with activated endothelial cells within peri- and intra-tumor vessels 
involved in tumor neo-angiogenesis, as also observed in meningioma. On the 
contrary CD105 expression is absent or very weak in the vascular endothelium of 
normal tissues [161-163]. 
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CD105 was proposed as putative renal cell carcinoma stemness marker [164] which 
confers self-renewal ability and concurs to chemo-resistance in human kidney 
cancer [165].  
However, CD105 expression was also reported in human meningioma. In particular, 
in rhabdoid meningioma CD105-positive cells had a significant proliferative activity 
and self-renewal ability and co-expressed surface mesenchymal progenitor cell 
markers (vimentin and SOX2) [166, 167].  
CD105 could represent a specific marker for detection of neo-vessels in 
meningioma, in comparison to pan-endothelial markers and its presence is 
significantly correlated to the growth fraction and histological grade of 
meningiomas. Importantly, it has been proposed that the levels of CD105 could 
have a prognostic impact on the overall survival and recurrence risk of this 
neoplasia.  
1.4 CHEMOKINES 
Cellular physiological processes, as survival, proliferation and differentiation are 
mediated by both direct cell-cell (or cell-matrix) interactions and secreted signaling 
molecules (e.g. growth factors, hormones, cytokines, chemokines).   
Signaling by secreted molecules can be classified according to the distance over 
which the signal acts, as 
1. autocrine: the cell produces a factor which stimulates itself;  
2. paracrine: the factor secreted by one cell type affects adjacent cells; 
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3. endocrine: the secreted molecule via the circulatory system acts on distant 
cells. 
In general, these integrated signals lead to the stimulation or repression of gene 
expression, by binding to intracellular or membrane receptors expressed by target 
cells. Among signaling molecules, chemokines are a family of small chemotactic 
cytokines (8-10 kDa) produced by cells and secreted into the extracellular space to 
guide cell migration, particularly of lymphocytes [168].  
The term chemokine derives from chemotaxis (directional movement of cells or 
organisms in response to chemical gradients [169, 170] and the Greek "-kinos, 
movement".  
Firstly, chemokines were discovered as chemoattractant of immune cell, such as 
granulocytes, neutrophils and eosinophils, monocytes and lymphocytes. 
Approximately 50 proteins with a highly conserved monomeric structure belong to 
the chemokine families, and more than 20 known receptors interact with them 
[171].  
According to their amino acid sequence, chemokines have been classified into four 
subclasses based on the position of their two N-terminal cysteine (C) residues: C 
(with a single cysteine residue); CC (with two adjacent cysteines); CXC (with a 
variable amino acid between cysteines), and CX3C (with 3 variable amino acids 
between cysteines) [172, 173].  
Cysteine conserved motif imposes the formation of two disulfide bridges [174]  and 
structural characteristics are related to chemokine functions [175]. CC chemokines 
generally recruit eosinophils, T cells, monocytes, basophils, natural killer (NK) and 
dendritic cells (DC); CXC chemokines attract polymorphonuclear cells such as 
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neutrophils [176]. C chemokines have only two members XCL1 (lymphotactin-α) and 
XCL2 (lymphotactin-β). CX3CL1 (fractalkine) is the only member of the CX3C group 
and it is secreted and linked to the surface of cells with chemoattractant and 
adhesion molecule roles. 
 
Figure 2 Structure of the 4 chemokine classes: all chemokines have peptide chains (in light blue) 
and disulphide bridges (in black). CX3C chemokines have also a hydrophobic domain (in purple) 
with mucine-like domain (in blue). Figure adapted from Wikipedia: 
https://en.wikipedia.org/wiki/Chemokine 
 
Chemokines and their receptors are promiscuous and redundant; many chemokines 
usually interact with several receptors, while some receptors can bind different 




Figure 3 The chemokine universe: chemokines and chemokines receptors families. Figure adapted 
from BioLegend.com 
Chemokines play a key role in a variety of physiological processes, in tissue 
development and homeostasis, and also are involved in the pathogenesis of tumors, 
supporting angiogenesis, cell migration, and metastasis. Linked to tumor 
development or viral infection, an up-regulation with modulation of proliferation, 
survival and migration has been described. In fact, cancer cells seem to use 
chemokine-induced chemotaxis to home in on specific tissues.  
 
1.4.1 Chemokine receptors 
Chemokines bind transmembrane receptors belonging to two families: conventional 
chemokine receptors (CCKRs), coupled to G-proteins (GPCR) for signal transduction 
and atypical chemokine receptors (ACKRs). To date 18 CCKRs have been identified in 
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humans, whose nomenclature is based on the predominant bound chemokine type 
(i.e. 10 CCR, 6 CXCR, 1 CX3CR, 1 XCR). To date 6 ACKRs have been identified: ACKR1, 
ACKR2, ACKR3 (previously named CXCR7), ACKR4, ACKR5 and ACKR6 [177].  
Human chemokine receptors usually contain approximately 340-370 amino acid 
residues, a short N-terminal end, seven helical transmembrane domains, and an 
intracellular C-terminus with serine-threonine residues for phosphorylation due to 
the interaction with ligands.  
Chemokine receptors present a sequence homology ranging from 25 to 80% at the 
amino acidic levels. Although they have highly similar primary sequences, they 
typically link to a limited number of ligands. 
Table 5 Chemokines and receptors classification 




C Chemokines    
XCL1 Lymphotactin-α Lymphotactin-α XCR1 
XCL2 Lymphotactin-β Lymphotactin-β XCR1 
CC Chemokines     
CCL1 I-309 I-309 CCR8 
CCL2 MCP-1 Monocyte chemoattractant protein -1 CCR2 
CCL3 MIP-1α Macrophage inflammatory protein-1α CCR1 
CCL4 MIP-1β Macrophage inflammatory protein-1β CCR1, 
CCR5 
CCL5 RANTES Regulated on activation normal T cell 
expressed and secreted 
CCR5 
CCL6 C10  CCR1 
CCL7 MCP-3 Monocyte chemoattractant protein-3 CCR2 
CCL8 MCP-2 Monocyte chemoattractant protein-2 CCR1, 
CCR5 
CCL9/CCL10 MRP-2  CCR1 
CCL11 Eotaxin Eotaxin CCR2, 
CCR3, 
CCR5 
CCL12 MCP-5   
CCL13 MCP-4 Monocyte chemoattractant protein-4 CCR1, 
CCR3, 
CCR5 




CCL15 Lkn-1 Leukotactin-1 CCR1, 
CCR3 
CCL16 LEC Liver-expressed chemokine CCR1, 
CCR2, 
CCR5 
CCL17 TARC Thymus- and activation-related 
chemokine 
CCR4 
CCL18 PARC Pulmonary-and activation-regulated 
chemokine 
CCR8 
CCL19 ELC Epstein-Barr virus-induced receptor 
ligand chemokine 
CCR7 
CCL20 LARC Liver-and activation-related chemokine CCR6 
CCL21 SLC Secondary lymphoid tissue chemokine CCR7 
CCL22 MDC Macrophage-derived chemokine CCR4 
CCL23 MPIF-1 Myeloid progenitor inhibitory factor-1 CCR1 
CCL24 MPIF-2 Myeloid progenitor inhibitory factor-2 CCR3 
CCL25 TECK Thymus lymphoma cell-stimulating 
factor 
CCR9 
CCL26 Eotaxin-3 Eotaxin-3 CCR3 
CCL27 ESkine ESkine CCR10 




CXC Chemokines     
CXCL1 Groα Growth-related oncogene α CXCR2 
CXCL2 Groβ Growth-related oncogene β CXCR2 
CXCL3 Groγ Growth-related oncogene γ CXCR2 
CXCL4 PF-4 Platelet-factor-4 CXCR3 
CXCL5 ENA-78 Epitelial cell-derived neutrophil-
activating factor 78 
CXCR1, 
CXCR2 
CXCL6 GCP-2 Granulocyte chemoattractant protein CXCR1, 
CXCR2 
CXCL7 NAP-2 Neutrophil-activating protein CXCR2 
CXCL8 IL-8 Interleukin-8 CXCR1, 
CXCR2 
CXCL9 Mig Monokine induced by γ-interferon CXCR3 
CXCL10 IP-10 γ-interferon-inducible-protein-10 CXCR3 





CXCL12 SDF-1 Stromal cell-derived factor-1 CXCR4, 
CXCR7 
(ACKR3) 
CXCL13 BCA-1 B cell-activating chemokine-1 CXCR5 
CXCL14 BRAK Breast and kidney chemokine unknow
n 
CXCL15  Lungkine unknow
n 
CXCL16 SR-PSOX Sexckine CXCR6 
CXCL17   CXCR8 
CX3C 
Chemokines 
    
CX3CL1 Fractalkine Fractalkine CX3CR1 
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Intracellular signaling responses depend on cell types, tissues and, physiologic or 
pathologic conditions [178]. It has been described that CXCR4, CCR2 and CCR5 form 
homodimers and, CCR2 and CXCR4 dimerization is necessary for signal transduction 
and occurs as a result of chemokine binding. Although the redundancy of 
chemokines-chemokine receptors network each receptor binds almost exclusively 
ligands of a single subclass. Thus, the chemokine receptors nomenclature is based 
on the chemokines group to which their ligands belong.  
Signal transduction induced by ligand-conventional receptor interaction is mediated 
by heterotrimeric (three distinct subunits) Gi-proteins and β-arrestins modulating 
cell adhesion, migration and proliferation. ACKRs act also in a G protein 
independent manner, and are mainly responsible for chemokine homeostasis, 
scavenging, gradient formation, and localization mediated by β-arrestins.  
Downstream complex pathways are activated by chemokine receptors such as PI3K 
and JAK/STAT pathways, phospholipase C (PLC) and calcium flux. Moreover, the 
activation of intracellular pathways such as p38 MAPK, ERK1/2, p21 kinase, Rho 
family of GTPases, Ras, and NF-kB trigger cell proliferation, survival, differentiation 





Figure 4 The redundancies and promiscuity of chemokine network. (Figure from Barbieri F, 2016). 
 
 
1.4.2 Chemokines and tumors  
Tumor cells and infiltrating immune cells release pro-inflammatory cytokines, which 
stimulate the production of chemokines. As result, the over-expression of 
chemokines and chemokine receptors on the tumor cell surface promotes tumor 
growth, angiogenesis and metastasis [181, 182]. Moreover, chemokines induce cell-
endothelial interactions, promoting transendothelial migration, and enhance tumor 
cell adhesion and invasion through integrin and matrix metalloproteinases (MMPs) 
activation [183, 184]. Furthermore, it has been demonstrated that chemokines as 
CC and CXC regulate immune cell infiltration of the tumor mass [183].  
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CXCL1 was initially identified as an autocrine growth factor in melanoma cells [185]; 
its activity is inhibited by specific antibodies or against its CXCR2 receptor, allowing 
a reduction in cell growth in vitro. 
CXCL8 also contributes to tumor progression, acting as mitogenic and angiogenic 
factor, and inducing cell migration. Higher levels of CXCL8 were observed in 
different human tumors such as malignant mesothelioma, melanoma, and 
pancreatic, prostate and colon cancers. CXCL8 has also been observed in human 
pituitary adenoma and neoplastic astrocytes. Anoxia increases CXCL8 expression in 
gliomas, and the use of CXCL8 asRNA inhibits human glioma cell growth in vitro 
[186, 187]. Studies have demonstrated that CXCL8 to promote endothelial cell 
proliferation and tumor vasculogenesis, and pro-angiogenic vascular endothelial 
growth factor (VEGF) and MMP-9 production [178, 188].  
Chemokines with ELR motif (N-terminal glutamate, leucine, and arginine-peptide) 
before cysteine domain such as CXCL1, CXCL5, CXCL7 and CXCL8 present pro-
angiogenic activity through the interaction with CXCR2 [189, 190].  Despite the ELR 
domain absence, CXCL12 is able to induce vascularization. It has been reported that 
also CCL2 of CC chemokines subgroup acts as direct mediator of angiogenesis [191, 
192]. On the contrary, α-chemokines as CXCL9, CXCL10 have angiostatic properties.  
In vivo studies showed that interaction between CXCL12 and VEGF induces 
angiogenesis, and CXCL12 is able to regulate chemotaxis in breast cancer [193].  
The expression of CXCL12 plays an essential role in metastasis, and the over-
expression of its receptor CXCR4 in the bone marrow and lymph nodes of mice has 
been observed [194]. A blocking antibody capable of neutralizing the expression of 
CXCR4 results in a tumor growth arrest [195]. In the last years, the involvement of 
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CXCL12 in tumor progression has emerged. CXCL12 and CXCR4 have been largely 
described in several human tumors as glioblastoma and neuroblastoma [196].  In 
particular, in glioblastoma cell lines CXCR4 is up-regulated and its inhibition reduce 
cell proliferation [197, 198].   
High levels of CXCR4 can be stimulated by cytokines such as TNF-α and IL-1β, 
present in large concentration in astrocytomas, and in some cases, induced directly 
from CXCL12. In addition, CXCR4 and CXCL12 have been described in human 
glioblastoma tissues and their amounts have been correlated with tumor 
malignancy [197, 199].  
Finally, CXCR7 impacts on the tumor formation in knockout mice [200] and, several 
studies reveal that CXCR7 up-regulation and cellular growth both in tumor cell lines 
and in human primary tumors. 
Although the majority of chemokines are involved in tumor growth, few of them 
show antitumor activity, inhibiting angiogenesis and activating immune response 
against the tumor. For example, CXCL9 and CXCL10 act both as angiostatic 
molecules and T lymphocyte chemoattractant. Interferon-γ induce expression of 
both CXCL9 and CXCL10 and through an interferon-dependent mechanism, they 
increase the anti-tumor effects of IL-12 [201].  
Moreover, the expression of p53 induces synthesis of the chemokine widely 
expressed in the CNS, fractalkine, which is able to attract monocytes and cytotoxic T 
cells demonstrating its involvement in immune prevention of malignant cell 
transformation [202].  
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1.4.3 The CXCL11/CXCL12- CXCR4/CXCR7 system in 
meningioma 
CXCR4 and CXCR7 are the two most highly conserved receptors among vertebrates 
and share the ligand CXCL12. The biological functions of the CXCL11-CXCL12/CXCR4-
CXCR7 network have been widely studied in tumors, including proliferation, 
survival, differentiation, angiogenesis, local invasion and metastasization of cancer 
cells.  
CXCL12 is a CXC chemokine that controls homeostatic processes such as 
embryogenesis, hematopoiesis, and angiogenesis. At the same time, a higher 
expression of CXCL12, or of a specific CXCL12 splicing variant, contribute to the 
onset or progression of diseases [203]. Firstly, CXCL12 was characterized as a pre-B 
cell growth factor and named stromal cell-derived factor-1 (SDF-1) due to its major 
natural source in bone marrow stromal cells [204].  CXCL12 acts as mitogenic 
modulator on its specific receptor CXCR4 for pre-B cells, T cells, dendritic cells, 
monocytes and hematopoietic precursors; it also supports hematopoietic 
precursors and CD34+ cell proliferation. However, CXCL12 action is not limited to 
these cell types, in fact its expression has been extensively described in different 
organs and tissues including the CNS. 
CXCR4 is a GPCR with an extracellular domain for CXCL12 binding. The binding 
CXCL12-CXCR4 triggers intracellular effects due to the interactions between G 
proteins and β-arrestin; consequently, adenylyl cyclase is blocked and PLC is 
activated via Src kinase, and PI3K and MAPK pathways activation entails gene 
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transcription that culminates in migration [184]. At last, CXCR4 is internalized via 
endocytosis in clathrin-coated vesicles and it can be recycled back to cell surface or, 
ubiquitinated and degraded [184, 205]. Several organs, including brain, in particular 
vascular endothelium, microglia, astrocytes and neurons express CXCR4 [175]. 
CXCL12 and its receptor CXCR4, involved in different human tumor cell 
proliferation, are expressed both in established meningioma cell lines [206-208]  
and in primary cultures [167, 209]. Knockout animals for CXCR4 and/or CXCL12 
clearly indicated the specificity interaction between these proteins, since the 
phenotypes of these animals are virtually identical [210-212]. CXCR4-/- or CXCL12 
homozygous animals died before birth, demonstrating that these molecules are 
essential for life in mice [213]. Fibroblasts of meninges release CXCL12, while CXCR4 
is expressed by stem cells of the external granular layer. Parallel to the role played 
in hematopoiesis, SDF-1 is involved in cerebellum development, attracting 
progenitor cells to their proliferative compartments.  
CXCR4/CXCL12 axis is regarded as promoter of tumor growth and metastases, 
through the inhibition of apoptosis, and promotion of angiogenesis, cellular 
proliferation and invasion [214]. A pharmacological interference with this network 
constitutes a promising opportunity to specifically target cancer cells and blood 
vessels [215, 216].  
CXCR7 (or ACKR3) has been identified as receptor for both CXCL12 and CXCL11 
(a.k.a. ITAC, shared with CXCR3) [194, 199], acting as a key regulator of the 
CXCL12/CXCR4 system, by heterodimerizing with CXCR4, and scavenging both 
CXCL11 and CXCL12. CXCR7 shows a 10-fold higher affinity towards CXCL12 than 
CXCR4 [211].  
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CXCR7, like CXCR4 and CXCL12, is widely expressed in fetal and adult SNC tissues 
and in tumor-associated vasculature and it may have an important role in tumor 
neo-vascularization [217-220]. Intriguingly, recent observations suggest a critical 
function of CXCR7 in modulating the activity of the ubiquitously expressed CXCR4 in 
tumor formation [221, 222]. A diffuse CXCR4, CXCL11 and CXCL12 protein 
expression has been detected in meningioma tissues, while CXCR7 was mainly 
present in a subset of tumor vessels [216]. Moreover, the levels of CXCR7 mRNA in 
meningioma tissues are significantly increased along with higher tumor 
aggressiveness and a positive correlation between the levels of CXCL11 and CXCL12 
was observed [220, 223].  
CXCL11 (or ITAC: interferon-inducible T-cell α-chemoattractant) initially described 
as CXCR3 ligand, shows also high affinity for CXCR7; it is expressed in different cell 
types such as leukocytes, fibroblasts and endothelial cells, following stimulation 
with interferon γ (IFN-γ) and interferon β (IFN-β), and to a lesser extent from 
interferon α (IFN-α) [211, 224]. In particular, it is highly expressed in leukocytes of 
peripheral blood, pancreas, liver and astrocytes, moderately in thymus, spleen and 
lungs and in low level in intestine, placenta and prostate [225]. CXCL11 attracts 
activated T-helper lymphocytes and natural killer (NK) cells, acting on CXCR3 and 
CXCR7 receptors [211, 226]. It also induces calcium release in T cells activated by 
the binding to CXCR3. On the contrary, CXCL11 has no activity on unstimulated T 
cells. CXCL11 plays an important role in CNS diseases involving the recruitment of T 
cells, and in epidermal immune responses. The interaction between CXCL11 and 
CXCL12 and their receptors plays also a significant role in the progression and 
metastasis of various human tumors [227].  As example, a recent study revealed a 
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significantly higher expression of CXCL11 in colorectal cancer tissue than in the 
normal colon tissue [228]. Furthermore, Gao Y. et al demonstrated that silencing of 
CXCL11 inhibits the in vitro migration and invasion and in vivo metastatic ability of 
colorectal cancer cells [228].  
 
Figure 5 Transduction pathway regulated by the CXCL11/CXCL12- CXCR4/CXCR7 axis. CXCL12 binds 
CXCR or CXCR7. These two distinct receptors can form homodimers or heterodimers. The binding of 
CXCL12 to CXCR4 leads preferentially to the association of Gi protein. Cell survival, proliferation and 
chemotaxis are promoted though MAP and PI3K/Akt intracellular signaling pathway. Activation of 
CXCR7 or CXCR4/CXCR7 heterodimer or internalized CXCR4 promotes β-arrestin-mediated signaling. 
Dashed lines show inhibitory pathway as CXCL12 internalization and subject to lysosomal 
degradation due to binding CXCR4 and CXCR7. 
58 
 
1.4.4 Pharmacological targeting of CXCR4 and CXCR7  
As mentioned above, chemokines and their receptors, in particular CXCL11-
CXCL12/CXCR4-CXCR7, play a key role in tumor growth, progression and metastasis. 
On the other hand, they are essential for in vivo development and hematopoiesis 
and, blocking this axis can lead to side effects [181, 229].  Several classes of CXCR4 
inhibitors have been developed, among low molecular weight [230]. In the early 
1990s AMD3100 (also known as plerixafor or Mozobil®, Sanofi) was originally 
synthetized to block HIV infection. AMD3100 is a bicyclam, in which two cyclam 
rings (1,4,8,11-tetraazacyclotetradecane) are linked through an aromatic bridge. 
AMD3100 acts as a CXCR4 antagonist, and at very high concentrations is an 
allosteric agonist of CXCR7 [231]. 
 
Figure 6 Structure of AM3100 
 
The anti-HIV activity of AMD3100 is due to the block of the interaction of gp120 
with CXCR4 during viral entry [232, 233], subsequently the observation from phase 
I/II studies that this molecule promotes leukocytosis, sustained by the mobilization 
of hematopoietic cells to the blood, AMD3100 (plerixafor) was approved by FDA 
and is used to mobilize hematopoietic stem cells from the bone marrow for 
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transplantation, in patients with hematological cancers such as non-Hodgkins 
lymphoma, leukemia and myeloma [230, 234]. Moreover, recent studies reveal 
AMD3100 ability to inhibit CXCL12-induced tumor cell migration in vitro and in 
animal models of breast, ovarian, pancreatic and colorectal cancer, pituitary 
adenoma, malignant melanoma and glioblastoma [235-237].   
To define specific functions of CXCR7, CXCR7-specific small molecule agonists 
inhibitors of this receptor have been developed for this purpose in recent years, 
including CCX771, CCX754 and CCX733 (Chemocentyx, Inc.), which compete for 
CXCL12 binding to CXCR7 at nanomolar concentration, also preventing agonist-














Figure 7  Pharmacological inhibition of CXCR4 with AMD3100 and CXCR7 with CXC771 
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2. Rationale and Aims of the Thesis  
Meningiomas are the most common primary intracranial tumors. They are divided 
into three grades of malignancy, showing progressive increased risk of recurrence. 
In most cases, surgical resection is the definitive therapy; however, grade II and 
grade III have 5-year recurrence rates of about 50% and 90%, respectively, and a 
significant mortality; in particular, 10-year survival for malignant meningioma is 
almost 78% for people age 20 to 44 and only about 40% for over 75 years old 
persons. Importantly, about 20% of grade I tumors also recur in 5 years either for 
the growth of residual tumor or through the progressing to a higher pathologic 
grade.  
This unpredictable clinical evolution represents a serious therapeutic challenge, 
since few molecular and biological information are currently available to predict the 
biological history of the tumor (for example histologically benign meningioma may 
behave as malignant tumors), and limited treatment options, especially for non-
operable and relapsed meningioma patients, have been developed.  
Therefore, identification of novel cellular and molecular factors related to and/or 
determining meningioma aggressive biological behavior and recurrence risk is a 
major research goal of the current research. Similarly to other brain tumors such as 
gliomas, meningiomas show high molecular and cellular heterogeneity. The classical 
theory of cancerogenesis was radically challenged after the cancer stem cell (CSC) 
identification. Despite the stochastic hypothesis, in which the same tumorigenic 
potential is maintained by all cells within the tumor mass, a hierarchical model, 
proposing only CSCs responsible for tumor initiation and progression and for 
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maintaining tumor heterogeneity, was developed and is now considered the most 
reliable [134, 135]. CSCs, also called tumor-initiating cells (TICs), are characterized 
by self-renewal and multi-lineage differentiation abilities like normal stem cells. The 
presence of stem-like cells plays an essential role in the genesis of several malignant 
tumors, sustaining tumorigenicity, chemo- and radio-resistance, metastasis, and 
recurrence. 
This new model led to the search for innovative therapeutic approaches aimed to 
kill CSCs to eradicate the tumor growth.  
The definition of CSCs is largely based on functional properties, including self-
renewal, ability to differentiate into different tumor-specific cell lineages, drug 
resistance, invasiveness and migration activity, and, more importantly, the retaining 
of the tumorigenic potential, as shown by in vivo animal experiments. Conversely, 
the expression of specific stem cell-related markers, often used to select tumor-
derived subpopulations does not define CSCs also because phenotypically different 
CSC subpopulations are present in each tumor. 
Recently, CSCs and their functional role have also been studied in benign tumors. In 
fact, some biological features of CSCs, such as spherogenesis (index of self-renewal) 
and expression of putative stemness markers (SOX2, NANOG and OCT4), have been 
identified in benign tumor cell populations; however, to date, the presence of CSCs 
in meningioma and their contribution to the clinical evolution of these tumors has 
been scarcely characterized.  
Meningioma cells, isolated from human surgical tissues able to form spheres in vitro 
in serum-free medium conditions, and expressing heterogeneous candidate stem 
markers such as CD133, CD105, CD44, Sox2, and nestin have been proposed as 
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stem-like cells. Among them, CD105 (cluster of differentiation molecule 
105)/endoglin, a transmembrane glycoprotein, has been proposed as a potential 
stem cell marker in many human cancer, including meningioma.  
CSCs reside in the tumor niche, composed of both tumor and normal cell types with 
diverse functions (immune cells, fibroblast, endothelial cells): CSCs tightly interact 
with these cell subsets via a complex mutual signaling leading to stemness 
maintenance, tumor growth, vascularization and invasion/metastasization. 
Chemokine signaling has a central role in sustaining both bulk tumor cell 
proliferation and CSC maintenance and functions, driving proliferation, migration 
and angiogenesis. In particular, the CXCR4/CXCR7-CXCL12/CXCL11 system promotes 
tumor progression in a variety of solid neoplasms, and CXCR4 is often 
overexpressed in CSCs. In this context, investigating the supportive activity 
mediated by chemokine-receptor pairing in CSCs will be crucial to investigate the 
biology of meningioma stem-like cells and identify new signaling targets for 
effective therapeutic strategies.  
Central goal of the present study has been the identification, the expansion in vitro 
and the characterization of stem-like cells derived from post-surgical specimens 
derived from human meningiomas, to better understand their contribution to 
meningioma aggressiveness and the malignant behavior of otherwise apparently 
benign phenotype of a grade I tumor subset. This aim will be pursued selecting 
primary meningioma cultures for putative CSCs by growing in stem cell-permissive 
medium (additioned with EGF and bFGF and devoid of FCS), following the initial 
protocol used to isolate neural stem cells, and already used in our laboratory to 
enrich primary cultures of human glioma and pituitary adenoma cell cultures. These 
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cells will be compared with cells grown in standard 10% serum-containing medium, 
as in vitro model of the “non-stem” differentiated tumor cells composing the bulk of 
the tumor mass. 
Then meningioma stem-like cell subpopulation will be compared with “non-stem” 
cells for biochemical and biological features ascribed to CSC:  
- proliferation rate;  
- ability to self-renewal (generation of meningospheres);  
- differentiation ability;  
- expression of stemness markers; 
- vascular mimicry. 
Furthermore, I analyzed the proliferative, pro-invasive and pro-angiogenic effects of 
the CXCR4-7/CXCL11-12 chemokinergic axis in meningioma stem cells as compared 
to their differentiated counterpart to assess whether a different regulation, likely 
derived from the niche compartment, between the two populations might occur. 
The specific aims of this study can be summarized in the following points:  
 Samples collection and in vitro expansion of a statistically significant number 
of primary meningioma cultures; 
 Isolation and characterization of putative CSCs in human meningioma; 
 Analysis of differential CD105 expression between stem-like and “non-stem” 
cell populations derived from human meningiomas; 
 Evaluation of the expression of CXCL11/CXCL12-CXCR4/CXCR7 system in 
putative CSCs and differentiated meningioma cells;  
 Analysis of the response to the CXCL11 and CXCL12 chemokines of the stem-
like and “non-stem” meningioma cells through in vitro assays for 
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proliferation, migration and tube formation; 
 Establishment of the individual role of the chemokine receptors CXCR4 and 
CXCR7 in the above described effects by pharmacological targeting using the 





3. Results and discussion 
3.1 Patients and meningioma tissues 
During the research activity of my Ph.D. course, between November 2015 and 
November 2018, thirty-seven consecutive meningioma samples were collected 
under sterile conditions from the Neurosurgery Unit of the Ospedale Policlinico San 
Martino – IRCCS of Genova (Prof. G. Zona). Informed consent was obtained from all 
patients. Soon after surgery, meningioma tissues were divided into two parts: one 
was formalin-fixed and paraffin-embedded for histopathological diagnosis, and the 
other was maintained in 0.9% NaCl solution at 4°C, transferred to the laboratory 
within 2h and immediately processed for cell isolation. When available, a tissue 
fragment was stored at -80°C for RT-PCR analysis.  
Each sample was coded with consecutive number-year of collection to preserve 
privacy of patients. Diagnosis was assessed at the Pathology Unit of the Ospedale 
Policlinico San Martino – IRCCS (Prof. J.-L. Ravetti), according to the WHO 
classification of CNS tumors. Individual clinical and pathological features of patients 
and tumors are reported in Table 6.  
Patient cohort included 2 non-meningeal tumors (1 neurinoma and 1 vascular 
lesion) which were excluded from further analyses. Proliferative index evaluated by 
Ki-67 positivity was about 5.1 % (range 0.1-60.0%) in grade I tumors, and 8.7% 
(range 2.1-15.0%) in grade II.  
It is worthy of note that 3 patients showed recurrent tumors, one of these, graded 




Table 6 Clinicopathological characteristics of meningioma patients and tissues 








1 M9-15 M 42 Posterior 
fossa 
1 M 1.6 5 4 N 
2 M1-16 F 75 Convexity dx 1 M 3.5 5 3 Y 
3 M2-16 M 78 Convexity dx 1 M 7.2 5 5 N 
4 M3-16 F 50 Temporobasa
l sx 
1 M 2.4 5 3 Y 
5 M4-16 F 54 spinal D5 1 M 3.5 3 1 Y 
6 M5-16 F 62 Convexity sx 1 M 2.3 3 2 Y 
7 M7-16 M 60 Convexity dx 1 M 1.4 2 3 Y 
8 M8-16 F 52 Falcine 1 M 2.5 5 3 Y 
9 M9-16 F 82 Convexity dx 1 M 1.4 3 2 Y 
10 M10-16 M 79 Falcine 1 M 4.2 4 3 Y 
11 M11-16 M 67 Convexity sx 1 An 5.1 3 2 Y 
12 M12-16 M 65 Orbital roof 
dx 
1 N.D 5.0 4 3 N 
13 M1-17  F  62 Posterior 
fossa  
1 M 4.1 4 2 Y 
14 M2-17  M  75 Cerebellopon
tine angle 
1 M 5.8 4 2 N 
15 M3-17  M  83 Convexity sx 1 M 60.0 4 5 Y 
16 M4-17 F 58 Posterior 
fossa 
1 M 2.0 4 5 Y 
17 M5-17 M 65 Convexity dx 1 M 2.7 4 4 Y 
18 M6-17 F 67 Convexity dx 1 T 2.3 2 4 Y 
19 M7-17 F 49 Tuberculum 
sellae 
1 M 2.5 4 5 N 
20 M8-17 F 59 Sfenoid ridge 
alar 
1 M 2.7 4 4 Y 
21 M9-17 M 64 Convexity° 1 F/P 2.1 1 1 Y 
22 M1-18 F 68 Sphenoid 
ridge alar° dx  
1 M 8.1 5 4 Y 
23 M2-18 F 48 Posterior 
fossa sn 
1 T 7.2 5 3 N* 
24 M3-18 M 77 Neurinoma      - 
25 M4-18 F 80 Convexity dx° 2 A 15.0 5 4 Y 
26 M5-18 M 71 Convexity sx 1 M 3.1 4 4 Y 
27 M6-18 F 66 Convexity sx 2 A 9.1 5 1 Y 
28 M7-18 F 59 Tuberculum 
sellae 
1 T 3.9 pos pos N* 
29 M8-18 F 47 Parasagittal 
dx 
1 T 2.5 4 1 Y 
30 M9-18 F 79 Convexity dx 1 P 2.5 2 3 Y 
31 M10-18 F 75 Convexity sx 1 F 1.4 2 4 Y 
32 M11-18 M 65 Vascular 
malfomation 
     - 
33 M12-18 F 53 Convexity sx 1 P 0.1 4 5 Y 
34 M13-18 F 75 Posterior 
fossa 
1 M 2.1 2 4 Y 
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35 M14-18 M 70 Posterior 
fossa dx 
2 A 2.1 5 4 Y 
36 M15-18 F 30 Convexity sx 1 M 7.0 4 4 Y 
37 M16-18 M 47 Cerebellopon
tine angle sx 
1 M 1.2 4 4 Y 
 
Sex: M=male; F=female.  
Histotype: M=meningothelial; An=angiomatous; T=transitional; F=fibrous; 
P=psammomatous; A=atypical; N.D.= not determined.  
PgR and EMA immunohistochemical score:1=negative, 2= rare positivity, <5% positive 
cells, 3= focal positivity (5-20% positive cells), 4= positivity (20-60% positive cells); 5=high 
positivity (>60% positive cells).  
Long term culture: N=no; Y=yes; N*= contaminated. 
 
 
Among the 35 meningioma patients, 22 were females and 13 males, with a female-
to-male ratio of 1.7:1 which is in accordance with literature meningioma gender 
distribution; the mean age was 63.3 years. All the patients did not receive 
preoperative treatments.  
The majority of such tumors were located supratentorially, commonly in the 
cerebral convexity (17/35), or in the posterior fossa (6/35) and in the region of 
sphenoid ridge. As expected, the majority of tumors were WHO grade I (32/35), and 
only 3/35 were graded WHO II; moreover, the meningothelial subtype was 
predominant (22/35, 63%), while others were distributed among different 
morphological subtypes as summarized in Table 7.  
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Table 7 Overview of meningioma patients and tissues 
 
Overall the tumors entered in our study reflect the histopathologic pattern of 
distribution expected for human meningiomas, with a great majority of WHO grade 
I “benign” tumors, known to have an indolent clinical course, but comprising a 
subgroup of tumors showing an aggressive behavior in which WHO grading did not 
match with prognosis. Moreover, our patient’s series includes 3 cases graded as 
WHO II atypical tumors, generally characterized by high variability in recurrence 
pattern. Overall, beside WHO grade III meningiomas which unfortunately display a 
nearly 100% 5-year recurrence rate, meningiomas entered our study are grade I and 
II tumors, which potentially represent challenging tumor types for clinical 
management. Indeed, histotype, grading, location, extent of resection and 
proliferative activity, although useful for gross tumor classification, did not help 
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predicting tumor behavior and recurrence [240]. Currently definite prognostic 
markers and cellular and molecular characterization are lacking, needed to 
understand the biological basis of meningioma aggressiveness and identify potential 
therapeutic target 
3.2 Isolation and characterization of putative CSCs 
from human meningiomas 
From November 2015, when I started my PhD in Neuroscience, to 2018, 28 primary 
cell cultures have been obtained from 35 individual postsurgical specimens of 
human meningioma collected in the laboratory of Pharmacology directed by 
Professor Tullio Florio of University of Genova.  
In fact, 5 primary cultures from meningiomas which did not yield sufficient number 
of viable cells and/or long-term cultures and 2 cultures that were contaminated. 
Firstly, tumor samples have been mechanically dissociated to obtain single cell 
suspensions using sterile forceps and scalpels; suspensions were then filtered 
through a 70 μm strainer to remove possible impurities and fibrous tissue 
aggregates, plated in DMEM/F12 containing 10% FBS, and allowed to attach to 
culture flasks. Within 1 week, primary meningioma cultures were obtained and 
grew in vitro as a monolayer (Figure 8).  
Medium change was performed at least twice before the experiments to remove 
red blood cells and cell debris. Cell morphology was observed by an inverted 
microscope and difference among cultures from different tumor histotypes was 
detectable (Figure 8): initially, primary cultures appeared as spindle- or round-
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shaped cells which progressively attach to the substrate within 2 days, acquiring 
typical morphologies, reflecting the heterogeneous appearance of meningiomas, 
after about 1 week: meningothelial meningioma cells (M4-17) comprised a majority 
of spindle morphologies and some rounded cells; fibroblast-like spindle cells were 
observed in transitional meningioma cultures (e.g. M7-18, Figure 8) while  the 
psammomatous type (M9-18, Figure 8), was characterized by round groups of cells 
mixed with branched cells. Cells M4-18, derived from an atypical tumor, possessed 
some cellular processes and intracellular granularity (Figure 8). 
 
 
Figure 8 Morphologic characterization of four primary meningioma cultures derived from different 
histotypes: M8-17 meningothelial, M4-18 atypical, M7-18 transitional, M9-18 psammomatous. 





After 1 week in culture, cells were split and maintained in two different media:  
1. Stem cell-permissive medium containing growth factors (EGF and bFGF) in 
the absence of serum, hereafter these cultures were named as “STEM”; 
2. DMEM/F12 FBS 10% medium containing FBS, but devoid of growth factors 
used for primary cell cultures, allowing them to grow and to differentiate 
and these cultures are identified as “DIFF”. 
Cells were grown under the two culture conditions for at least 7 days before 
performing subsequent analyses and experiments. In vitro, single-cell suspensions 
enriched in stem cells and grown in stem permissive medium, usually originated 
non-adherent spheres, and this culture method is also frequently used to expand 
both normal and cancer stem cells.  
However, these cultures show several limitations, such as sphere size, density and 
composition heterogeneity, different exposure of surface and central cells to 
treatments, technical problems to analyze and reproduce functional parameters of 
floating aggregates. Therefore, to obtain more experimentally manageable STEM 
cultures, Matrigel-coated dishes/flasks were used throughout our study to grow 
cells as attached monolayer. Matrigel is an extracellular matrix originally widely 
used for human embryonic and adult stem cell cultures and successfully used also 
for CSC adherence, maintenance and long-term proliferation. We found that 0.2% 
Matrigel, is sufficient for adherence and growth of meningioma STEM cells, and 
ensures that CSCs retain stemness properties including self-renewal, multilineage 
differentiation, without entering in the differentiation program as already observed 
in glioblastoma stem cells [241]. 
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It should be pointed out that even if a large number of primary cultures were 
obtained, the isolation of meningioma cells presents technical difficulties and these 
cells are not immortal, often showing limited proliferation over time, and hence the 
number of cells available could be not sufficient to perform all experiments in the 
same sample. The same limitations were also observed in the isolation of other 
stem-like cells from human benign tumors such as pituitary adenomas [146]. 
Preliminarily, to characterize the phenotype of the cell obtained from tissue 
disaggregation, a series of markers have been analyzed by Fluorescence Activated 
Cell Sorting (FACS) analysis in M5-16 derived cells after the first week in culture 
(passage 0, total), and one week after splitting in the two different culture 
conditions (passage 1: STEM and DIFF). The panel of analyzed proteins, showed in 
Figure 9, includes CD105, a marker of mesenchymal cell stemness, previously 
suggested to be expressed by putative meningioma CSCs, and endothelial (CD31 
and CD34) or hematopoietic lineage markers (CD14, CD19, HLA-DR, CD45), and 
CD106, also known as vascular cell adhesion molecule 1 (V-CAM1).  
 
Figure 9. Immunophenotype of meningioma-derived cells at P0 (total) and at P1 in STEM or DIFF 
medium, by flow cytometriic analysis.   
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Unselected primary culture contains a great majority of CD105 positive cells 
(77.5%), often co-expressing CD106 protein (75.5%). Moreover, HLA-DR (41.8%) has 
also been found, highlighting the presence of antigen presenting cells as 
macrophages, B-cells and dendritic cells (Figure 9). The expression of other 
hematopoietic markers, CD14, mainly expressed by macrophages (14.2%), and CD45 
presented on all differentiated white blood cells (14.1%), indicate the presence of 
hematopoietic cells. Endothelial cell markers CD34 (1.3%) and CD31 (0.6%) are 
expressed in a small number of cells. Overall these data suggest that the primary 
cultures isolated from the tissue include a large subpopulation of CD105-positrive 
cells and, as expected still contain some cell types of hematopoietic origin.  
After the first subculture (P1) in for a week in STEM and DIFF conditions, 
hematopoietic markers are no longer present while high levels of CD105 (98.5% in 
STEM and 86.9% in DIFF) and CD106 (75.5% in STEM and 86.9% in DIFF) positive 
cells remain in both conditions as reported in Figure 9. 
This indicates that further purification of primary cells is achieved, by medium 
change, sub-culture and selective media, removing unattached cells. 
To analyze the morphology of STEM and DIFF cells, cultures have been observed by 
transmitted light microscope and ZOE™ Fluorescent Cell Imager microscope after 
staining with Vybrant™ CFDA SE Cell Tracer Kit to detect viable cells (Figure 10). 
STEM and DIFF cultures exhibited divergent cell morphologies: in STEM medium 
cells showed heterogeneous size and shape, with short cellular processes, and 
lacked remarkable granularity, while in DIFF medium appeared enlarged, flattened 




Figure 10. Morphologic characterization of meningioma STEM- and DIFF-cultures. A-B) 
Representative morphological appearance of STEM- and DIFF cells grown as monolayer (Original 
magnification 10x). C-D) Representative fluorescent images of viable green fluorescent STEM- and 
DIFF- cells. Original magnification 10X. 
 
To delve deeper into the features of these meningioma cells, we measured the 
growth rates of 6 cultures, derived from the same tumors, but differentially 
selected under STEM and DIFF conditions.  
Six cases (M1-18, M4-18, M5-18, M6-18, M9-18, and M13-18) were cultured for 7 
days and daily analyzed for cell proliferation, by MTT reduction assay; individual 
data are plotted in Figure 11A. All tested meningiomas evidenced a significant 
difference in growth profile when maintained in STEM and DIFF conditions; indeed, 
starting from the third day, in 5 out of 6 meningiomas, the STEM proliferation was 
constantly at least 2-fold higher in than the time-matched proliferation of the 
correspondent meningioma in DIFF medium (Figure 11, panel A). Figure 11 panel B 





Figure 11. A. Time-course growth curves of STEM (in red) and DIFF (in blue) of meningioma cells 
assessed daily for seven days by MTT. Each point represents the mean ± S.D. B. Cumulative growth 





Since medium was changed every three days in culture, we speculate that the 
reduced differences between the two conditions, that can be observed after three 
days, is due to growth factors exhaustion in the STEM medium; after medium 
renewal the difference in proliferation was promptly recovered .It is possible to 
appreciate that, whereas the stem-permissive conditions allowed a constant growth 
for up to 7 days at least in 4 out of 6 cultures, under differentiation conditions cell 
grow slowly was arrested after 2-3 days. These differences are relevant to our study 
because they support the hypothesis that it is possible to maintain long-term 
growing stem-like subpopulations from meningioma tissues.  
Hence, we investigated more in detail the presence of hallmarks of stemness in 
both STEM and DIFF cells such as the sphere formation, which represents one of the 
functional features of CSCs by evaluating self-renewal activity. Spherogenesis was 
analyzed in 9 primary STEM cultures, plated on Matrigel-free polystyrene dishes and 
allowed to grow for seven days in STEM medium, and their DIFF counterparts were 
shifted in STEM medium for the same time. Cultures were monitored daily and at 
day 7, phase-contrast images were taken to evaluate the presence of floating 
spheroids (Figure 12).  
 
Figure 12 Representative morphological appearance of (A) STEM cells, without Matrigel in STEM 
medium, forming spheres and (B) cells originally maintained in DIFF medium and shifted in STEM 
medium, still growing as adherent monolayer. Cultures were observed after 7 days in vitro and 
photographed by phase contrast microscopy. Original magnification 20X. 
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Five out of nine STEM cultures grown without Matrigel were able to form 
meningospheres, spheroids of variable size, shape and compactness, while four of 
them grew as both sphere-like aggregates and adherent cells. In contrast, almost all 
DIFF cultures (7/9) even in the presence of growth factors were not able to form 
spheroids and still adhere to the substrate. Only M1-18 and M9-18 meningiomas 
formed albeit small, aggregates (Table 8). The latter observation indicates that in 
these cultures differentiation was not complete and possibly partially reversible, 
although self-renewal ability was still much lower as compared to STEM cultures, at 
least as far as spherogenesis assay is concerned. 
Table 8 Sphere forming ability of meningioma cultures 
 STEM DIFF 
 Spheroid Spheroid 
M10-16 ++ -- 
M1-17 ++ -- 
M3-17 ++ -- 
M5-17 +- -- 
M6-17 +- -- 
M8-17 ++ -- 
M1-18 +- +- 
M9-18 +- +- 
M15-18 ++ -- 
 
++=floating spheroid; --=firmly adherent cells; +-=mixed cultures with spheroid and 
adherent cells. 
 
Several markers such as CD44, SOX2, CD44, OCT4, NANOG and CD133 have been 
proposed to determine and/or mark stemness in solid tumor cell subpopulations, 
mostly referring to malignant lesion, but also identified in different benign tumors 
including meningioma [155]. Thus, we investigated the expression of above markers 
in STEM- and DIFF-cells by immunofluorescence (IF), as shown in the panel reported 
in Figure 13.  
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Overall, the current analysis showed that the expression of all putative stemness 
markers was higher, although not completely homogeneous, in STEM than in DIFF 
cultures, where only scattered cells were positive for CD44 and OCT4, showing that 
cell grown in stem cell permissive medium retain, and enrich in cell with CSC 
characteristics.   
 
Figure 13 Immunofluorescence analysis of putative stemness markers in STEM and DIFF cells.  
Representative immunostaining of M8-17 cells for Sox2 (green), CD44 (red), OCT4 (red), NANOG 
(red) and CD133 (green); nuclei were counterstained with DAPI (blue). Original magnification 20X. 
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In different tumors, but particularly in meningioma, CD105 expression has been 
proposed as potential stem cell marker which could allow the identification of the 
subpopulation of cells responsible for tumor recurrence. In particular, a study 
performed in rhabdoid meningiomas found a direct correlation between CD105 
expression levels and the proliferative activity; moreover, CD105-positive cells 
revealed self-renewal ability and co-expression of mesenchymal stem cell markers, 
as vimentin and Sox2 on their surface [166, 167]. 
On these premises, to delve deeper into the role of CD105 in the two meningioma 
cell subpopulations we selected, we performed IF analysis in STEM and DIFF cells 
(Figure 14). 
 
Figure 14 Representative IF staining of primary cultures maintained in STEM (A) or DIFF (B) 
conditions with anti-CD105 antibody (in red, panel A; in green, panel B) and DAPI for nuclear 
counterstain (blue). Original magnification 20X. 
 
Unexpectedly, differently from other stem cell markers analyzed, we observed a 
similar pattern of CD105 immunostaining in cells grown in both conditions, 
suggesting that, at least in our series of cultures this marker does not define stem-
like meningioma subpopulations. 
To further verify this result, in parallel with Sox2, CD105 protein level was analyzed 
by Western Blotting. STEM and DIFF cell lysates from three meningiomas, M8-17, 
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M1-18, and M5-18, were prepared and WB resulting bands for target proteins and 
loading controls are reported in Figure15A; densitometric analysis of CD105 and 
Sox2 protein level reported as ratio of -actin level, is depicted in figure 15B-D. 
 
Figure 15. A. Representative immunoblot analysis of CD105 and Sox2 protein levels in 3 STEM and 
DIFF meningioma cultures. Immunoblot for β-actin was used to normalize the results for the total 
content of proteins. B-C. Quantification of CD105 and Sox2 protein levels, reported as densitometric 
values of blots in panel A and expressed as CD105/β-actin ratio and Sox2/β-actin ratio. D. Mean 
CD105 and Sox2 levels ± S.D., collecting data from the 3 meningiomas (***p<0.001, t-test). 
 
Heterogeneous CD105 protein levels were observed among different cultures but 
they did not significantly differ between STEM and DIFF conditions: STEM M8-17 
CD105 level resulted lower than in DIFF M8-17 (CD105/β-actin: 0.58 vs. 0.91); in 
M1-18 the amount of CD105 was higher in STEM than in DIFF (CD105/β-actin: 1.02 
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vs. 0.60), while M15-18 presented approximately equal level of CD105 in both STEM 
and DIFF cultures (1.95 vs. 1.96) (Figure 15B). Interestingly, Sox2 expression was 
higher in all 3 STEM cultures (Sox2/β-actin: 1.03 vs. 0.79 M8-17; 0.85 vs. 0.65 M1-
18, and 0.91 vs. 0.73 M5-18) than in DIFF cells (Figure 15C), reaching a statistically 
significant difference (p < 0.01). The lack of differences in the expression of CD105 
in the two meningioma subpopulations we isolated contrasts with the proposed 
hypothesis of CD105 as putative CSCs marker of human meningiomas.  
However, since CD105 is mostly indicated as mesenchymal stem cell (MSC) marker, 
and the presence of MSCs and their differentiation are critical features in tumor 
progression, we further investigated the possible mesenchymal potential of the 
meningioma cultures. To clarify the possible association of MSC features with 
meningioma progression, the expression of three typical MSC markers, CD105, 
CD90 and CD73, in both STEM and DIFF cells was examined by FACS analysis in 8 
meningiomas. As reported in the histogram of the Figure 16 no significant 
differences in the percentage of positive parental cells of CD105 antigen between 
STEM (89.6%) and DIFF (82.5%) have been observed.  
 
Figure 16 Expression of CD105, CD90 and CD73 mesenchymal markers in STEM and DIFF cells, by 
flow cytometric analysis.   
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A higher, although not significant, expression of CD90 antigen in DIFF cells (90.3%) 
than in STEM cells (59%) was observed and, in contrast, higher level of CD73 was 
found in STEM vs. DIFF cells (93.1% vs. 78.6%).  
Overall, high co-expression of CD105, CD90 and CD73 surface markers in both STEM 
and DIFF cells, although at different levels, could indicate the minimal 
mesenchymal-stem like phenotype of these cells as already reported in grade I 
meningiomas [242]. 
Since the ability to differentiate into mesenchymal lineages (adipocytes, osteocytes 
and chondrocytes), is required to define the MSC type, we investigated the 
differentiation potential of STEM and DIFF cultures, by culturing cells from four 
meningiomas in a defined medium for osteogenesis differentiation for 10 days, and 
calcium deposits were stained with 2% Alizarin Red S.  
Slight morphological changes were observed in STEM cells as compared with DIFF 
cells; in particular, in 2 meningiomas, the increase in calcium deposition, even 
though relatively low, was evident in STEM cells, as reported in Figure 17A.  
To quantify the amount of Alizarin Res S –staining, calcified mineral was dissolved 
with 10% acetic acid and samples were read by colorimetric detection at 450 nm 




Figure 17. Osteogenic differentiation of meningioma cells. A. Representative pictures of STEM and 
DIFF cells, stained with Alizarin Red S, from M8-17, maintained in Osteogenesis Differentiation 
medium for 10 days. B. Quantification of osteogenic formation in four meningioma cultures, STEM 
(white bars) and DIFF (grey bars) (***p< 0.001, *p<0.05, STEM vs. respective DIFF cultures, t-test). 
 
STEM cells from both M3-17 and M8-17 meningiomas showed a significant 3-fold 
higher presence of calcium deposits than respective DIFF cells.  
In the same cultures we also evaluated adipogenic differentiation; by maintaining 
cells in Adipogenesis Differentiation medium for 21 days. The presence of 
intracellular lipid vacuoles typical of adipocytes, was detected by using Oil Red O 
staining. Intracellular lipid vacuoles developed only in STEM cells from M9-17 
meningioma (Figure 18); while both STEM and DIFF cells derived from the other 
cultures were not able to differentiate. In only 2 cases in which sufficient cells were 





medium; however, neither STEM cells nor DIFF cells were able to adapt and survive 
the chondrogenic differentiation culture conditions. 
 
Figure 18 Adipogenic differentiation. Representative pictures of STEM and DIFF cultures from M9-
17, maintained for 21 days in Adipogenesis Differentiation medium and stained with Oil Red.  
 
Tri-lineage differentiation seems not consistently occur in our meningioma cultures 
belonging to grade I tumors, in agreement with Lim et al. (2013) that reported MSC 
features in cells isolated from meningioma only in few cases (3/10) of WHO II 
tumors, whereas none of 10 benign meningiomas fulfils MSC phenotyping criteria. 
Therefore, the role of CD73, CD90 and CD105 proteins in meningioma might be 
related to other functions, and needs to be further investigated. 
To elucidate whether the presence of high levels of mesenchymal markers in 
meningioma might identify a subset of cells involved in EMT, a process which 
contributes tumor aggressiveness, we analyzed the expression of epithelial cadherin 
(E-cadherin) and neural cadherin (N-cadherin) known as key players of EMT. During 
EMT E-cadherin is downregulated while mesenchymal marker proteins such as N-




Both STEM and DIFF cells expressed N-cadherin, while E-cadherin resulted absent, 
as detected by IF (Figure 19).  
 
 
Figure 19 Immunofluorescence analysis of E-cadherin (green) and N-cadherin in STEM and DIFF 
cells. Representative immunostaining of M8-17 cells; nuclei were counterstained with DAPI (blue).  
Original magnification 20X. 
 
The expression of E-Cadherin is regulated by transcription factors such as Snail, 
Twist, thus we performed a quantitative RT-PCR on four meningioma STEM and 
DIFF cultures to analyze Twist, Snail, Vimentin and E-Cad and N-Cad mRNA levels. 
Results did not reveal a distinct pattern of expression between STEM and DIFF cells. 
These results suggest that the different culture conditions did not enrich cells with 
EMT phenotype, and other factors sustain the distinctive features of STEM and DIFF 
cultures.  
 
3.3 Meningioma STEM cells display enhanced 
migration capacity and tube formation 
To further characterize the putative stem cell-like biological features of the different 
meningioma cultures we selected, the migratory and angiogenic (vascular mimicry) 
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activities were tested in the two populations. The acquisition of migration capacity 
that allows tumor cells to change their morphology and position, and to pass from a 
circumscribed and confined tumor to invasive disease, represents a typical feature 
of cancer, mainly sustained by CSCs, responsible for tumor diffusion and recurrence 
mediated by cell invasion of extratumoral structures thus preventing the complete 
surgical removal of all the tumor cells. 
We performed trans-well migration assay in 24h-starved STEM and DIFF cells 
derived from 12 meningioma cultures; in these experiments, cells were labeled with 
a fluorescent dye prior to seeding in basal medium (serum-and growth factor-free) 
onto the upper chamber of FluoroBlok™ multiwall insert.  
Basal medium, used as negative control, or complete medium containing 10% FBS, 
used as chemoattractant for cell migration, were added in the lower chamber. 
Migration through the pores of the membrane at the bottom of the insert, was 
evaluated after overnight incubation by counting migrated cells (3 microscopic 
fields for each condition, performed in duplicate) with a confocal microscope.  
Overall, although there was some migration in wells containing basal medium in 
both STEM and DIFF cells, slightly more evident in the STEM counterpart, there was 
a significant (nearly 5-fold) increase in cellular migration in the presence of FBS, 
used as chemoattractant, of STEM cells as compared to the correspondent DIFF 
cells (Figure 20). Importantly, a highly significant migratory activity occurred at 
shorter timing than the proliferative activity of both cultures, thus allowing a 




Figure 20. Trans-well migration assay. Representative migration pictures of STEM and DIFF cultures 
from M1-17 (upper panels). Following o/n incubation, fluorescent cells that had migrated to the 
underside of the filters were counted on images acquired by confocal microscopy. In the lower 
panel, histogram represents the mean ± s.e.m. of data from 12 primary meningioma cultures 
(**p<0.01, t-test).    
 
These results confirm that STEM cells have higher migratory capacity than DIFF 
cells.  
Meningiomas are highly vascularized tumors, and angiogenesis is essential for their 
growth, likely due to de novo vessel formation sustained by CSCs, as previously 
observed in other solid tumors. 
Therefore, we tested the angiogenic activity in 8 meningioma cultures using the in 
vitro tube formation assay, a well-established test which evaluates the ability of cells 
plated in a defined medium, on a gel to form three-dimensional capillary-like 
tubular structures (vascular mimicry).  
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The ability of CSCs to differentiate into functional endothelial cells has been largely 
studied in malignant tumor; in particular, glioblastoma CSCs closely interact with 
the endothelial niche, determining a directional movement of endothelial cells 
through the release of chemotactic molecules as vascular endothelial growth factor 
and CXCL12 in an autocrine/paracrine manner [243-245]. This generation of 
functional vascular structures contributes to tumor survival altogether with 
neoangiogenic processes. STEM and DIFF cells were shifted from their respective 
culture media to Basal EndoGRO medium (hereafter ENDO-BASAL) and, after 24h, 
were seeded on Matrigel-coated slides and further incubated in both basal medium 
(negative control) and EndoGro medium containing VEGF (hereafter ENDO-
COMPLETE as positive control), formulated to sustain endothelial cell growth in 
vitro. Cells developing cell-cell and cell-matrix interactions was monitored by phase-
contrast microscopy a within 6h tube formation was evident. 
As reported in Figure 21, under basal condition STEM cells displayed a slightly 
higher ability to form tubules than DIFF cells, whereas STEM cells form vessel-like 




Figure 21 Tube formation assay. Representative pictures of M1-17 meningioma (upper panels). 
Angiogenesis was quantified by mean count of loop number ± S.D. (*p<0.05, STEM vs. DIFF cells, t-
test) (lower panel). 
 
In vitro tube formation assay confirm that STEM cells initiate vascularization, 
undergoing a trans-differentiation process.  
As possible molecular correlate of these results, we observed by RT-PCR that STEM 
cells express 6-fold VEGFR than DIFF cells in 6 meningioma cultures (Figure 22).  
 
 
Figure 22 VEGFR2 expression in six meningioma STEM 
and DIFF cultures. Quantitative RT-PCR analysis 
showed that STEM cells express at higher level VEGF 
receptor 2 transcript. Results are given as relative fold 
increase in mRNA expression. Data were normalized to 
expression of the β-actin and 28s genes. Bars represent 






Altogether these results clearly demonstrate that different subpopulations are 
present within menigiomas that can be differentiated for some of the recognized 
features of CSCs. In particular, cells selected by growing in stem cell-permissive 
medium display, as compared to differentiated meningioma cells, 1) higher 
proliferation rate; 2) ability to self-renew; 3) expression of stem cell markers; 4) 
mesenchymal differentiation ability (although in this case only few STEM cultures 
show a differentiation ability); 5) higher migration ability; 6) ability to 
transdifferentiate in endothelial-like cells.  
All these features allow us support the hypothesis that CSC-like cells are present in 
meningioma and thus efficacious pharmacological therapies should be able to 
target this population. Conversely, the proposed use of CD105 as a marker for the 
putative CSC population was not confirmed by our results, since it was expressed 
similarly in both cultures. 
3.4 CXCR4/CXCR7-CXCL11/CXCL12 axis in human 
meningioma cells 
The communication between cells and the tumor microenvironment, the so-called 
niche, is critical for tumor growth, angiogenesis and metastasis. Several molecules, 
including growth and chemotactic factors, adhesion receptors, membrane bound 
and cytokine ligands and receptors, are involved in the regulation of proliferation 
and self-renewal of CSCs. Moreover, vascular factors induce cell-endothelial 
interaction, promoting cellular migration and invasion. The main chemotaxis-
regulating factors, also protect CSCs from standard therapies as chemo- and radio-
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therapy. Pharmacological treatments that act on niche-mediated tumor protective 
effects could therefore represent a successful strategy against CSCs. In particular, 
CSCs derived from several human malignant tumors, as well as putative stem cells 
obtained from benign tumor such as pituitary adenomas [146], overexpress 
chemokine receptors CXCR4 and CXCR7 [197]. In particular, chemokines and 
receptors within the CXCR4/CXCR7 – CXCL11/CXCL12 axis are involved in the 
interactions between CSCs and their niche.  
For these reasons, to better understand the biological functions of this chemokine 
system in human meningioma, we evaluated the expression levels of CXCR4, CXCR7, 
CXCL12 and CXCL11 in six meningioma cultures, comparing matched STEM vs. DIFF 
cells, by quantitative Real Time PCR (qRT-PCR) (Figure 23).  
 
Figure 23  CXCL11, CXCR7, CXCR4  and CXCL12 expression in meningioma STEM and DIFF cultures. 
Quantitative RT-PCR analysis showed that STEM cells express, at different levels, chemokine and 
chemokine receptor transcripts. Results are given as relative fold increase in mRNA expression. Data 
were normalized to expression of the β-actin and 28s genes. Bars represent the mean of six distinct 





Interestingly, STEM and DIFF cells express two distinct sets of chemokines and 
chemokine receptors. In particular, STEM cells preferentially express CXCR4 and 
CXCL11 mRNA; conversely, in DIFF cells higher mRNA content for CXCR7 and CXCL12 
were detected (Figure 23).  
Receptors’ expression is inversely correlated to that of their ligands, therefore it 
could be hypothesized a downregulation of the receptors in the subset of cells 
which highly expressed the respective main ligand. This result suggests that in 
meningioma STEM cells the CXCL12-CXCR4 system plays a relevant role in stemness 
and underline an individual role of CXCR4 and CXCR7 in meningioma stem cell 
population. 
On this basis, to expand and validate the results obtained by quantitative RT-PCR, 
protein levels of CXCR4 and CXCR7 have been investigated using 
immunofluorescence as displayed in the pictures in Figure 24. DIFF cells seem to be 
more homogeneously positive for CXCR7, while STEM counterpart showed mainly 
CXCR4-positive cells but also CXCR7-expressing cells.  
 
Figure 24 Immunofluorescence for CXCR4 (green) and CXCR7 (red) in STEM and DIFF cultures. 
Nuclei were stained with DAPI (blue). Original magnification 20X. 
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3.5 CXCL11 and CXCL12 enhance proliferation of 
meningioma STEM cultures  
To better understand the role of each chemokine in biological functions of 
meningioma cells, we focused our attention on the modulation of the proliferative 
potential of STEM and DIFF cultures Cells from meningioma cultures plated in a 
EGF/bFGF- of FCS-deprived medium for 24h to avoid growth factor interferences, 
were treated with 25nM CXCL11 or 25nM CXCL12; cells were allowed to grow for 
further 24h and the effects on cells were analyzed by MTT assay (Figure 25).  
 
Figure 25 Effect of CXCL11 and CXCL12 stimuli on the proliferation of STEM (red) and DIFF (blue) 
meningioma cultures by MTT assay. Each point represents the mean value of individual 
meningioma, expressed as % of respective untreated control cells (CTR), taken as 100%. Horizontal 
lines depict the mean value of the 6 cases (* p < 0.05, vs. respective CTR; t-test).  
 
Both CXCL11 and CXCL12 induced significant increase in cell proliferation of STEM 
cells, while chemokines did not promote proliferation of DIFF cells. 
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This observation reinforces the hypothesis that not only STEM and DIFF cells 
express differential pattern of chemokine-receptor mRNAs and proteins, but also 
the growth of STEM cells, differently from DFF cells, is predominantly regulated 
through CXCL12 signaling, likely via CXCR4. Interestingly, also CXCL11 promotes cell 
survival and growth, suggesting a cooperation between CXCR4-CXCR7 shared 
ligands. 
3.6 ERK1/2 activation mediates chemokine effects in 
meningioma STEM cultures  
CXCL11 and CXCL12 act via ERK1/2 activation, a crucial intracellular pathway 
promoting cell proliferation in several cellular subtypes [246]. Thus we investigated 
CXCL11- and CXCL12-induced signal transduction in six STEM cultures by evaluating 
ERK1/2 phosphorylation. STEM cells were starved in a growth factor-deprived stem 
cell permissive medium for 24h and then, stimulated with CXCL11 and CXCL12 at 
the concentration of 25 nM, for 5 min; then, the amount of phosphorylated ERK1/2 




Figure 26 CXCL11 and CXCL12 induce ERK1/2 phosphorylation in meningioma STEM cultures.  
A. Representative immunoblot analysis of p-ERK protein level induced by CXCL11 and CXCL12 in M4-
16 STEM culture. Immunoblot was re-probed for α-tubulin was used to verify the equal loading of 
total proteins in samples and normalize the results. B.  Quantification of p-Erk level by densitometric 
analysis as mean ± S.D., collecting data from the 6 meningiomas (**p<0.001 vs. controls, t-test). 
  
Collectively, we observed that CXCL12 induced a significant increase in 
phosphorylation of ERK1/2 (about 2-fold) compared to control levels. CXCL11 
treatment also determined an increase in ERK1/2 phosphorylation that was slightly 
higher as mean level (2.3-fold vs. controls) than that induced by CXL12, although it 
was not statistically significant, due to the high variability of the response among 
the 6 cultures. In fact, the high variability depends on the presence of two 
meningiomas that did not respond to the CXCL11 stimulus, while CXCL11 induces an 
increase in phosphorylation of ERK1/2 in the others four meningiomas.  
These data confirm that chemokines, in particular CXCL12, play a role in 
meningioma proliferation, via ERK1/2 activation, likely through an 
autocrine/paracrine mechanism mediated by CXCR4 and CXCR7.  
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3.7 Migration of meningioma STEM cultures is 
potentiated by CXCL11 and CXCL12  
Chemokines were initially identified as mediators of leukocyte cross-talk and 
migration, both in physiological and pathological conditions, and the CXCL12/CXCR4 
signaling has been described to play a major role in tumor metastasis and migration 
in a variety of tumor types. Heterogeneity in the tumor cell population is able to 
promote invasion and metastasization, as caused by the presence of cancer stem 
cells, whose motility is markedly enhanced and associated with high tumor-
initiating and metastatic capacity.  
In order to verify whether a gradient of CXCL11 and CXCL12 could enhance 
meningioma cell migration, directional migration towards a chemotactic stimulus 
(CXCL11 or CXCL12) was assessed in 8 fluorescent-labelled meningioma cultures by 
trans-well assay, as reported in Figure 27A.  
Chemotactic migration was quantified by counting the number of migrated cells 
from images of cells on the bottom well membrane captured after o/n incubation 








Figure 27 Effects of CXCL11 and CXCL12 on the migratory potential of STEM and DIFF cells.  
A. Representative migration pictures of the bottom side of the membrane at the 15h time-point, and 
histograms of quantification of STEM and DIFF cultures plated in the top chamber of a transwell 
plate, and CXCL11 (25 nM) or CXCL12 (25 nM) faded to the bottom chamber from meningioma M1-
17. B. Histogram represents the mean ± s.e.m. of chemotaxis quantification from 8 cultures 
(***p<0.001, **P<0.01; vs. respective CTR, t-test). 
 
The migratory response of STEM cells to CXCL11 and CXCL12 was significantly higher 
as compared with untreated controls, highlighting the stem-like features of these 
cultures. Otherwise, no cell migration was observed in response to both CXCL11 and 
CXCL12 in DIFF cultures. The lack of cell migration response towards chemotactic 





Meningioma, commonly does not metastasize outside the CNS, however, brain 
invasion is frequent and represents a key clinical parameter included among the 
criteria used to classify grade II tumors in the last WHO classification and, more in 
general to identify an aggressive behavior of meningiomas, considering that a 
percentage of benign tumors behaves atypically as far as prognosis due to brain 
invasive ability. 
CXCL12/CXCR4 axis controls cell migration and chemotaxis, and, likely, in STEM 
meningioma cell this chemotactic behavior does not only affect the homing of CSC-
like subpopulation within the tumor niche, but also contributes to infiltration of the 
adjacent brain tissues. Histopathological studies in meningiomas describe either 
groups of tumor cells invading brain parenchyma or single cells spreading into 
neural tissue regardless of tumor location [247]. The process by which meningioma 
cells spread out the primary tumor represents a major determinant of poor 
prognosis favoring tumor recurrence due to incomplete surgery for the presence of 
cluster of cells dispersed in the brain [248]. The highly migratory nature observed in 
STEM meningioma cultures further support their stem-like nature, an extremely 
interesting feature taking into account the histopathological benign origin of these 
cells and outlining the partially inconsistent biologic value of histopathologic 
grading in meningiomas. In addition, CXCL11- and CXCl12-dependent migration of 
meningioma stem-like cell likely arise in vivo as a consequence of a chemokine 
gradient which act as chemoattractant for tumor cell expressing specific receptors, 
creating directional migration within brain parenchyma. As observed in other solid 
tumors, CSC-like subpopulation in meningioma may be characterized by higher 
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plasticity and inherent migratory potential than more differentiated cells favoring 
their robust response to chemoattractants in tumor microenvironment.  
3.8 CXCL11 and CXCL12 promote tube formation in 
STEM cultures 
Given the high vascularization which characterizes meningiomas, and the pro-
angiogenic activity of CXCR4 and CXCR7 in several tumors, we completed the 
functional study evaluating the capacity of CXCL11-CXCL12/CXCR4-CXCR7 
interactions to stimulate in vitro formation of vascular structures. Tube formation 
assay was performed in 8 meningioma STEM and DIFF cultures. In order to induce 
tube formation, cells were shifted from their respective culture media in Basal 
EndoGro medium (in the Figure 28, named ENDO-BASAL), and after 24h cells were 
plated on Matrigel-coated slides in the presence of 25 nM CXCL11 or CXCL12. The 
formation of vessel-like structures has been monitored after 6h by phase-contrast 
microscopy. Under basal condition STEM cells were already able to form tubes than 
DIFF cells although slightly, whereas STEM cells displayed higher capacity to 
transdifferentiate into endothelial-like cells, giving rise to a considerably larger 








Figure 28 Effects of CXCL11 and CXCL12 on formation of vascular structures of STEM and DIFF cells. 
A. Representative pictures of STEM and DIFF meningioma M1-17 cells, stimulated with CXCL11 (25 
nM) or CXCL12 (25 nM). B. Angiogenesis from 8 cultures was quantified by mean count of loop 
number ± S.D. (*p<0.05, **p<0.01, vs. respective CTR, t-test).  
 
Overall, these results highlight two main observation: first of all, that chemokines, 
and CXCL12 and CXCL11 in particular, are main regulators of relevant biological 
activities likely involved in the aggressive behavior of meningiomas (i.e. 
proliferation, migration and neo-angiogenesis), but that, independently on the 





subpopulations of cells display a selective ability to respond to the chemokines. In 
particular, being higher proliferative, migratory, and tube formation activities were 
observed in STEM cultures and almost absent in DIFF cultures, we hypothesized that 
the atypical clinical course of some grade I meningioma might by related to a larger 
presence of this subpopulation. Thus, if these results will be validated in larger 
series of meningiomas, their histological identification mat represent a novel 
prognostic index for those with unpredictable clinical course.  
3.9 Pharmacological inhibition of both CXCR4 and 
CXCR7 inhibits CXCL11- and CXCL12-induced 
proliferation, tube formation and migration of 
meningioma STEM cells 
On the basis of the ability of  CXCL11 and CXCL12 to trigger proliferative, migratory 
and angiogenic responses, selectively observed in STEM culture subpopulation, we 
decided to delve deeper into the individual contribution of receptors for these 
chemokines. CXCR4 and CXCR7 role in meningioma STEM cell functioning was 
pursued by pharmacological inhibition of this chemokine system using antagonists 
for CXCR4 (AMD3100) and CXCR7 (CCX771). However, the pharmacology of these 
receptors is rather complex, since CXCR4 is bound only by CXCL12 and antagonized 
by AMD3100, but CXCR7 is bound by both CXCL12 and CXCL11 (which also activates 
CXCR3) and is blocked by CCX771 (although a single report suggested that AMD3100 
could act as partial agonist for CXCR7 [231], but no subsequent studies confirmed 
this evidence). Notwithstanding, the combination of the aforementioned agonists 
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and antagonists is to date the best pharmacological approach to define the 
biological roles of these receptors.  
Thus, 24h-starved STEM cells, derived from 6 meningiomas, were incubated with 
CXCL11 (25 nM) or CXCL12 (25 nM), in the presence or absence of AMD3100 (1μM) 
and CCX771 (10 nM) for 24h before performing MTT assay (Figure 29). 
 
Figure 29 Proliferation on six STEM cultures stimulated with 25 nM CXCL11 or 25 nM CXCL12 and 
treated with the inhibitors of CXCR4 (AMD3100, 1 μM) or CXCR7 (CCX771, 10 nM) by MTT assay 
(*p<0.05, vs. respective CTR, t-test).  
 
The ability of both chemokines to significantly increase STEM cell proliferation was 
significantly hampered in the presence of the antagonists. Treatment of cultures 
with the CXCR4 antagonist AMD3100 prevented CXCL12-induced proliferation, 
while CCX711 reduced the stimulation of both CXCL11 and CXCL12. Since the effect 
of both ligands were blocked by both antagonists, our data allows us to hypothesize 
that the proliferative effect of chemokines is mediated by both CXCR4 and CXCR7, 
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and that, as far as CXCL12, the single inhibition of each of its receptors is enough to 
prevent the activation of proliferation. In this context, it has to be remarked that 
CXCR4 and CXCR7 have been reported to dimerize in the presence of ligand 
activation, thus it is likely that the antagonists exert their action preventing CXCL12-
dependent dimer formation or blocking the signaling of preformed dimers. Further 
studies will be necessary to address this issue. 
In parallel, we evaluated, by Western Blot, CXCL11- or CXCL12-dependent ERK1/2 
phosphorylation/activation in 4 STEM meningioma cultures, after pre-treatment 
with AMD3100 (1μM) or CCX771 (10nM) (Figure 30). CXCL12 (25nM) induced a 
statistically significant ERK1/2 activation in STEM meningioma cells, while CXCL11 
stimulation of ERK1/2 phosphorylation, although clearly evident in few samples, on 
the average did not reach a statistical significance.  
However, pre-treatments with AMD3100 and CCX771 completely prevented 
CXCL12- and CXCL11-activation of ERK1/2 (Figure 30).  
Overall, above results suggest that survival/proliferation of meningioma STEM cell 
culture caused by chemokine stimulation of CXCR4 and CXCR7 is mediated by 




Figure 30 Quantification of p-ERK1/2 level by densitometric analysis as mean ±  S.D., collecting 
data from  4 meningioma STEM cultures (*p<0.05, vs. respective CTR, t-test). 
 
As previously observed in the Figure 26, in which six different meningiomas were 
analyzed, the effect of the stimulation of CXCL11 is not significant since of the four 
meningiomas investigated, two not respond with the activation of ERK1/2. Although 
average, an increase in phospo-ERK1/2 is observed. 
Next, we investigated the impact of the blockade of CXCR4 and CXCR7 signaling, 
using AMD3100 and CXC771 on cell migration (Figure 31). The significant CXCL11 
and CXCL12-induced chemotaxis (Figure 31) is reverted to basal levels by both 
pharmacological antagonists, thus indicating that the migration depedent by these 
cxhemokine involves both receptors, and suggesting that blocking CXCR4-7 signaling 




Figure 31 Migration on 3 STEM cultures stimulated with 25 nM CXCL11 or 25 nM CXCL12 and 
treated with the inhibitors of CXCR4 (AMD3100, 1 μM) or CXCR7 (CCX771, 10 nM)                  
(*p<0.05, vs. respective CTR, t-test). 
 
These results are particularly relevant as far as the role of CXCR7. Indeed, CXCL12-
CXCR4 signaling has been previously implicated in migration and invasiveness of 
several tumor types, and, in particular, in the homing of cancer cells to the 
metastatic site; conversely, CXCL12 signaling in the migratory potential of tumor 
cells expressing CXCR7 and the mechanisms by which CXCR7-mediates invasion has 
been scantly investigated in most tumors including meningioma.  
We also analyzed the ability of pharmacologic inhibition of CXCR4 and CXCR7 to 
modulate chemokine-enhanced angiogenesis in vitro (Figure 32). AMD3100 and 
CCX771 treatment markedly reduced the tube formation induced by both CXCL11 
and CXCL12 in STEM meningioma cultures, bringing back the vessel-like structure 
formation to control levels. It is well known that CXCL12 regulates angiogenesis, 
mainly through its receptor CXCR4; while, also in this case, the role of CXCR7 in 
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angiogenesis is mostly reported in endothelial cell, being this receptor highly 
expressed in blood vessel of a variety of tumors. On the other hand, CXCR7 function 
in cancer stem cells is less definite. Taken together our results on the CXCL12-CXCR7 
interaction involved and likely sustaining stem phenotype of STEM meningioma is 
relevant in this high vascularized tumor. 
 
Figure 32 Tube formation assay on 3 STEM cultures stimulated with 25 nM CXCL11 or 25 nM 
CXCL12 and treated with the inhibitors of CXCR4 (AMD3100, 1 μM) or CXCR7 (CCX771, 10 nM) 





4. Conclusions  
Cancer stem cell (CSC) hypothesis propose that, within tumor cell heterogeneity, a 
small subpopulation of cells, named CSCs, is responsible for tumor formation, 
growth, spreading, and recurrence. Generally, CSC concept is applied to malignant 
tumors, while less is known about their role in benign lesions such as the majority of 
meningiomas. Nevertheless, the definition of CSC phenotype is challenging due to 
technical limitations, lack of univocal marker definition, different functional assays 
and heterogeneity of cellular hierarchy within both benign and malignant tumors.   
In this context, one main issue addressed in the research reported in this thesis has 
been the identification, isolation, and in vitro expansion of putative meningioma 
stem-like cells, from a large series of unselected human post-surgical meningioma. 
Moreover, this cell subpopulation has been challenged for multiple functional 
assays related to the known CSC activities.  
Our results highlight that different cell subpopulations are present within 
meningiomas, including stem-like cells which are able to survive and grow in stem 
cell-permissive conditions in vitro; these cells show remarkable distinctive features 
as compared to their “non-stem” counterpart: 1) higher proliferation rate; 2) ability 
to self-renew; 3) expression of several stem markers; 4) multilineage differentiation 
ability (although in this case only few STEM cultures show a mesenchymal-like 
differentiation ability); 5) increased migratory capacity; 6) capability to undergo the 
formation of tridimensional tube formation (vascular mimicry). Further studies are 
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currently in progress to demonstrate the in vivo tumorigenic activity of these cells, 
which represent the definitive proof of the CSC nature of these cells. 
As expected from meningioma histopathologic distribution and incidence, the great 
majority of the tumors entered in the study were grade I, morphologically benign 
lesions, but seldom exhibiting an aggressive clinical behavior, relapsing and 
undergoing malignant transformation. Grading and altered molecular pathways of 
meningiomas are often identified based on the bulk of tumor cells, therefore the 
biological features of meningioma stem cell-like subpopulation we isolated might 
help to obtain key information on their distinct role in meningioma aggressiveness, 
currently scarcely investigated. Moreover, this study was performed on early 
passage cell cultures, after the isolation from fresh surgical tissue, thus strictly 
reflecting the patients’ tumor landscape rather than obtainable using cell lines, is 
also relevant in the perspective of pharmacological studies. Indeed, 
pharmacological targeting of CSCs could represent a relevant and still unidentified 
novel strategy, in particular for recurrent, progressive and symptomatic 
meningiomas, for which to date there are no effective therapies. In this view, a 
future development of this work should be the assessment of the tumorigenic 
activity of meningioma stem-like subpopulation to obtain a better pre-clinical model 
to be exploited for both molecular and therapeutic studies. This study also 
contributes to improve the knowledge of mesenchymal cell markers (CD105, CD90 
and CD73) which have been proposed to identify putative meningioma stem cells, 
particularly CD105. In our series of meningioma cultures, CD105, was similarly 
expressed in both stem and “non-stem” cultures which also co-expressed CD90 and 
CD73. Therefore, we propose that CD105 is not a selective stem marker for 
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meningioma CSCs, and likely other mesenchymal stem cell surface proteins might 
play additional role in meningioma cells. Beside tumor heterogeneity, recent 
oncology studies attempted to include CSCs within tumor microenvironment and 
stem cell-like niche, to delve deeply in the mutual interactions between these 
structures that lead to tumor complexity. The communication between cells and 
tumor microenvironment, is critical for tumor growth, angiogenesis, and metastasis, 
all representing hallmarks of malignant transformation. In particular, CXCR4/CXCR7-
CXCL12/CXCL11 axis sustains proliferation, self-renewal, migration and invasion of 
CSCs in different cancers, while little is known in meningioma model. In this context, 
we analyzed the expression of the chemokines CXCL11-CXCL12 and their receptors 
CXCR4-7 in meningioma stem-like cells and “non-stem” cells, observing an inverse 
correlation between the expression level of ligands and their receptors. These 
results suggest that the upregulation of the ligands in subsets of cells might induce a 
chronic activation of the respective receptors in a paracrine/autocrine manner 
causing a phenotypical reduced expression of the receptor, and vice versa. Both 
chemokines selectively promoted in vitro proliferation, migration and tube 
formation of meningioma stem-like subpopulation, while “non-stem” cells did not 
respond to the chemokinergic stimuli. Overall, these results suggest the 
CXCL11/CXCL12-CXCR4/CXCR7 system plays a relevant role in meningioma stem cell 
maintenance and underline an individual role for CXCR4 and CXCR7 as pro-
angiogenic and pro-migratory mediator of the high vascularization and invasive 
features of aggressive meningioma. Our data, demonstrating a sustained CXCL12-
CXCR7 interaction in stem cell phenotype and functions is relevant since CXCR7 
activity in CSCs is less known and definite than CXCR4-dependent mechanisms, 
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adding further components in the CSC-microenvironment cell crosstalk. These data 
further suggest that stem cell subset do not passively reside within the tumor mass 
but also regulate the cell functioning by producing soluble factors such as 
chemokines. We speculate that the malignant phenotype of some grade I 
meningioma might by related to a larger presence of this subpopulation. CXCR4-7 
signaling could also represent a future clinical target, since effective therapeutic 
approaches antagonizing the activity of this receptor likely might also affect CSC-
tumor microenvironment crosstalk. Finally, we demonstrated the ability of CXCR4 
and CXCR7 antagonists (AMD3100 and CCX771, respectively), individually added, to 
completely prevent meningioma stem-like cell proliferation, migration and neo-
angiogenesis induced by both CXCL11 and CXCL12. These data indicate that 
meningioma stem cells functions are mediated by both CXCR4 and CXCR7, possibly 
acting as heterodimers, since the single inhibition of each of its receptor is sufficient 
to block the activity of both receptors. Formation of CXCR4-CXCR7 heterodimers, in 
the presence of ligand activation, seems to be crucial in the highly aggressive 
response of CSCs in several tumors. In meningioma cells, the antagonists exert their 
action preventing CXCL12-dependent dimer formation or blocking the signaling of 
preformed dimers; further studies will be necessary to address the inhibition of the 
chemokine pathway as a possible successful strategy against recurrent meningioma.  
In conclusions, we demonstrate that also in meningioma is present a cellular 
subpopulation endowed with several phenotypical and biological features of CSCs, 
that being under control of the CXCL12/CXCL11 chemokinergic system, might be 
pharmacologically targeted by selective antagonists of their receptors. 
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5. Materials and Methods 
5.1 Isolation and culture of human meningioma cells 
All meningioma samples were collected from the Neurosurgery Unit of the 
Ospedale Policlinico San Martino – IRCCS of Genova, after Ethical Committee 
approval and informed consent obtained from all patients.  
Thirty-seven surgical meningioma specimens were processed upon arrival in the 
laboratory, for single cell dispersion by mechanical disaggregation with sterile 
forceps and scalpels, and then filtered through a 70 μm strainer to remove possible 
impurities and aggregates.  
Cell suspensions were collected and were cultured in DMEM/F12 (1:1), 
supplemented with 1% penicillin-streptomycin (Lonza) and 2 mM L-glutamine 




Figure 33 Meningioma specimen derived from surgical resection (A); single cell dispersion by 





After 1 week, primary cultures able to grow as adherent cells, were harvested by 
enzymatic mean (Trypsin) to remove possible contaminating cells sub-cultured in 
two distinct media:  
1. STEM-culture in stem cell-permissive medium: DMEM-F12/Neurobasal (1:1) 
supplemented with 1% B27 (Life Technologies), 2 mM L-glutamine (Lonza), 
1% penicillin-streptomycin (Lonza), 10 ng/ml bFGF and 20 ng/ml EGF 
(Milteny Biotec); 
2.  DIFF-culture in DMEM/F12 medium containing FBS 10%: DMEM/F12 (1:1) 
supplemented with 1% penicillin-streptomycin (Lonza) and 2 mM L-
glutamine (Lonza), 10% FBS (Lonza). 
 
To obtain more experimentally manageable cultures, cells maintained in stem- 
permissive medium were grown in dishes/flasks coated with Matrigel (BD 
Biosciences) as monolayer.  
 
 
Figure 34 Isolation and growth of meningioma STEM and DIFF cells. 
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5.2 Fluorescence Activated Cell Sorting (FACS) 
 FACS analysis was performed to investigate the surface antigen expression profile 
of cells obtained from tissue disaggregation at passage 0, and of one week after 
splitting-cells in the two different culture conditions (p1).  
Cells were washed with 1 ml of FACS buffer (phosphate buffered saline, PBS/ EDTA 
2 mM, 0.5% bovine serum albumin BSA, 0.5%) and resuspendend with 
phycoerythrin-fluorescein isothiocyanate (FITC)-, Alexa Fluor 647-, or 
allophycocyanin-conjugated antibodies against CD105 (Miltenyi Biotec), CD31 
(Miltenyi Biotec), CD106 (Miltenyi Biotec), CD14 (BD Biosciences), HLA-DR (BD 
Biosciences), CD45 (BD Biosciences), CD34 (BD Biosciences) and CD19 (BD 
Biosciences). All antibody solutions were prepared in FACS buffer. The dead cells 
were excluded from analysis by adding 7-aminoactinomycin-D (7-AAD) (BD 
Biosciences). Data were acquired on BD FACSCanto II (BD Biosciences) and analyzed 
by BD FACSDiva software. 
With same preparation, cells were stained for CD105, CD90 and CD73 by Human 
MSC Phenotyping kit (Miltenyi Biotec), and resuspend in LIVE/DEAD® Fixable Aqua 
Dead Cell Stain Kit in accordance with manufacturer’s instructions (Molecular 
Probes, Life Technologies) Appropriate IgG isotype-matched antibodies and 
unstained cells were used as controls. Data were acquired on BD FACSCanto II (BD 
Biosciences) and analyzed by BD FACSDiva software. 
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5.3 Cell proliferation assay 
Mitochondrial activity, as index of cell viability, was evaluated by measuring the 
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
Sigma-Aldrich).  
Cells (5,000/well) were seeded in 48-well plates to allow exponential cell growth for 
duration of the assay (up to 7 days). Cells were incubated with MTT 0.25 mg/ml for 
2h, formazan crystals dissolved in 100 μl DMSO and absorbance measured at 570 
nm.  
MTT assay was also performed in 96-well plates containing 1,500/well and treated 
with chemokines (CXCL11 25 nM or CXCL12 25 nM), and in the presence of absence 
of the respective inhibitor: AMD3100 (1 μM) and CCX771 (10 nM) for 24h. 
5.4 Meningosphere-formation assay 
Cells deriving from both STEM and DIFF cultures were collected and resuspended in 
STEM medium, seeded in 6-well ultra-low attachment plates (Corning) at 50,000 
cells/well. Sphere formation was monitored for up to 7 days and cultures were 
analyzed by light microscopy; images of each individual well were acquired with a 
digital camera Leica ICC50 HD (Leica) mounted on a transmitted light microscope 
DM IL (Leica).  
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5.5 Immunofluorescence (IF) 
Cells (10,000/well) were plated on 8-well chamber slide (BD Bioscience), previously 
-coated with Matrigel for 30 min (STEM cells) or without coating (DIFF cells). After 
24 h, cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min, washed 
twice with PBS, permeabilized with PBS/0.1% Triton X-100, blocked with normal 
goat serum (NGS) (all from Sigma-Aldrich) and incubated with the following primary 
antibodies: Sox2 (mouse monoclonal, Abcam), Oct4 (rabbit polyclonal, Abcam), 
Nanog (rabbit polyclonal, Abcam), CD133 (mouse monoclonal, Novus Bio), CXCR4 
(mouse monoclonal, Abcam), CXCR7 (rabbit polyclonal, Abcam), CXCL11 (rabbit 
polyclonal, Abcam), CXCL12 (rabbit monoclonal, Abcam), E-cadherin (mouse 
monoclonal, Abcam), N-cadherin (rabbit polyclonal, Abcam), all diluted 1:100, and 
CD105 (mouse monoclonal, Abcam) diluted 1:200, in 2% NGS-PBS at r.t for 1 h. 
Fluorochrome-conjugated antibodies (goat anti-mouse and anti-rabbit Alexa Fluor-
568 or Alexa Fluor-488, Molecular Probes-Invitrogen) were applied, and nuclei were 
counterstained with DAPI (Sigma-Aldrich). Negative controls omitting primary 
antibodies were included in all the experiments. Coverslips were mounted with 
ProLongTM Gold Antifade Mountant (ThermoFisher). Slides were photographed with 
DM2500 microscope (Leica) equipped with DFC350FX digital camera (Leica).   
5.6 Western Blot  
Cultures were washed and lysed in a buffer containing 20 mM Tris-HCl pH 7.4, 140 
mM NaCl, 2 mM EDTA, 10% glycerol, 1% Igepal, 1mM sodium orthovanadate, 1mM 
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phenylmethyl-sulfonyl fluoride, 10mM NaF (all from Sigma-Aldrich), and the 
"Complete" protease inhibitor mixture (Roche Applied Science), for 10 minutes at 
4°C. Nuclei were removed by centrifugation (5,000 rpm at 4°C) for 10 min and total 
proteins were quantified using Bradford assay (Bio-Rad).  
Proteins (20-60 µg) were resuspended in Laemmli buffer (2% SDS, 62.5mM Tris, pH 
6.8, 0.01% bromphenol blue, 1.43 mM b-mercaptoethanol, 0.1% glycerol), 
subjected to 10% SDS-PAGE, electroblotted onto polyvinylidene of fluoride 
membrane (Bio-Rad) and probed with specific antibodies directed against CD105 
(endoglin, rabbit polyclonal, Santa Cruz), Sox2 (mouse monoclonal, Abcam), and 
beta-actin (mouse monoclonal, Cell signaling).  
Immunocomplexes were detected using a chemiluminescence system (BioRad 
Laboratories), and quantified by the ChemiDoc XRS apparatus (Bio-Rad 
Laboratories). 
When convenient, STEM culture and DIFF, culture media were deprived of growth 
factors and FBS, respectively, for 24 h before CXCL11 (25 nM) and CXCL12 (25 nM) 
stimuli, to remove possible interference. Thus, cells were treated for 5 min, in the 
presence or absence of the respective inhibitor: AMD3100 (1 μM) and CCX771 (10 
nM). As above, 40 μg of proteins were probed with specific antibodies direct against 
phospho-ERK1/2 (Cell Signaling Technology) and alpha-tubulin (mouse monoclonal, 
Cell Signaling).  
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5.7 Multilineage differentiation analysis 
The ability to differentiate into mesenchymal lineages (adipogenic, chondrogenic 
and osteogenic lineages) of putative meningioma CSCs was verified by switching the 
cultures into specific-enriched factors medium. Briefly, 15,000 cells were seeded 
and cultured in StemPro® Osteogenesis Differentiation medium (GIBCO®) replacing 
medium every 3 days, and after 10 days stained with 2% alizarin red S (Sigma-
Aldrich) to detect the formation of calcium deposits. Otherwise, adipogenesis 
differentiation ability was evaluated by seeding 25,000 cells in StemPro® 
Adipogenesis Differentiation medium (GIBCO®) for 21 days and replacing medium 
every 3 days. The presence of intracellular lipid vacuoles typical of adipocytes, was 
detected by using Oil Red O (Sigma-Aldrich) staining. Chondrogenic differentiation 
was assessed by plating 40,000 cells/well in NH ChondroDiff Medium (Miltenyi 
Biotec GmbH, Germany) for 21 days, replacing medium every 3 days. 
Chondrogenesis was confirmed using Alcian Blue staining (Sigma-Aldrich). 
Images were acquired with a digital camera Leica ICC50 HD (Leica) mounted on a 
transmitted light microscope DM IL (Leica).  
5.8 Cell migration assay  
STEM and DIFF cultures were labeled with the fluorescent dye Vybrant® CFDA SE 
Cell Tracer Kit (following the manufacturer’s instructions, for 15 min at 37°C. After 
30 min in DMEM at 37°C, in which CFDA will undergo acetate hydrolysis, cells were 
suspended and counted. Migration was performed in FluoroBlok™ HTS 96 multiwell 
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culture inserts (8 μm pore size, Corning) by seeding 15,000 cells to the upper 
chamber in 50 μL DMEM, and 225 μL DMEM supplemented with CXCL11 (25 nM) or 
CXCL12 (25 nM) or 10% FBS were placed in the lower chamber [249]. Each condition 
was performed in triplicate. After overnight incubation under 5% CO2 at 37°C, three 
microscopic fields of the lower surface of the filter in each well were acquired with 
a confocal laser scanning microscope (BioRad MRC 1024 ES). Intensity quantification 
of fluorescence of migrated cells was counted using "Analyze Particles" tool by 
ImageJ software (NIH, Bethesda, USA). 
5.9 Tube formation assay 
μ–Slide Angiogenesis (Ibidi) were coated with 10 μL Matrigel (BD Biosciences) and 
allowed to polymerize at 37°C for 30 min. After 24 h of starvation in EndoGroTM 
basal medium (Merck Millipore), 10,000 cells from both STEM and DIFF cultures, 
were seeded on Matrigel-coated wells and incubated at 37°C in EndoGroTM basal 
medium and EndoGROTM-VEGF complete medium (Merck Millipore) [250] for 6h to 
allow tube formation. Tube formation assay was also performed on cells treated 
with chemokines (CXCL11 25 nM or CXCL12 25 nM), and in the presence of absence 
of the respective inhibitor: AMD3100 (1 μM) and CCX771 (10 nM) for 6h.       
Tube formation in each well was photographed using a phase contrast microscope 
DM IL (Leica) and pictures were acquired with a digital camera Leica ICC50 HD 
(Leica). 
To quantify the results, the mean of loops, in which at least 3 tubes joined, were 
counted using the ImageJ software.  
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5.10 RNA extraction and quantitative real-time PCR 
(qRT-PCR) 
Total RNA has been extracted using the High Pure RNA Isolation Kit (Roche Applied 
Science, Manheim, Germany), according to the manufacturer's instruction and it 
has been retro-transcribed into cDNA using the iScript cDNA Synthesis Kit (BioRad 
Laboratories). Single stranded cDNA products were analyzed by real-time PCR using 
the SsoFastTM EvaGreen mix (BioRad Laboratories) on a CFX96 Touch real-time PCR 
(BioRad Laboratories). Cycling conditions were set at 94°C for 30 seconds, 60°C for 
30 seconds and 72°C for 30 seconds, for 35 cycles.  
Primer sequences have been designed on the mature transcript: 
 CXCL12: forward 5' - GCCCGTCAGCCTGAGCTACA- 3' 
reverse 5' - TTCTTCAGCCGGGCTACAATCT - 3' 
 CXCL11: forward 5' - GAGTGTGAAGGGCATGGCTA - 3' 
reverse 5' - TAAGCCTTGCTTGCTTCGAT - 3' 
 CXCR4: forward 5' - TTCTTCAGCCGGGCTACAATCT - 3' 
reverse 5' - GGAACACAACCACCCACAAGT -3' 
 CXCR7: forward 5' - CAACCCTGTCCTCTACAGCTTCAT – 3’ 
reverse 5' - TCATTTGGTGCTCTGCTCCAAG - 3' 
 VEGFR2: forward 5’ – CACCACTCAAACGCTGACATGTA – 3’ 
reverse 5’ – GCTCGTTGGCGCACTCTT – 3’ 
Human β-actin and 28s pre-designed PrimePCR pair primers (Bio-Rad) have been 
used as internal controls. Levels of target genes in each sample were normalized on 
the basis of housekeeping gene amplification and reported as relative values. All 
120 
 
qRT-PCR runs included negative controls without mRNA templates and cDNA 
transcription to check reagents for contaminations; moreover, melting- curve has 
been performed at the end of each amplification-run set in order to evaluated the 
specificity of the reaction. 
5.11 Statistical analysis 
Statistical significance between groups was assessed by t-test (unpaired, two-
tailed). 
Statistics were performed using Prism version 5.02 (GraphPad San Diego CA, USA). 
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